ALK4
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Y Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Log-Odds: Y Sites / Y Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A0A2R8Y4L2 | S95 | Sugiyama | HNRNPA1L3 HNRNPA1P48 | RPHKVDGRVVEPKRAVSREDsQRPDAHLTVKKIFVGGIKED |
| A5A3E0 | S1068 | Sugiyama | POTEF A26C1B | SLSTFQQMWISKQEyDEsGPsIVHRKCL_____________ |
| A5A3E0 | S939 | Sugiyama | POTEF A26C1B | VALDFEQEMATVAsSSSLEKsyELPDGQVItIGNERFRCPE |
| A5A3E0 | Y1062 | Sugiyama | POTEF A26C1B | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCL_______ |
| A5A3E0 | Y940 | Sugiyama | POTEF A26C1B | ALDFEQEMATVAsSSSLEKsyELPDGQVItIGNERFRCPEA |
| O00170 | T48 | Sugiyama | AIP XAP2 | FQDGTKATFHYRtLHsDDEGtVLDDsRARGKPMELIIGKKF |
| O00505 | S60 | Sugiyama | KPNA3 QIP2 | KRDEHLLKKRNVPQEEsLEDsDVDADFKAQNVTLEAILQNA |
| O00592 | T556 | Sugiyama | PODXL PCLP PCLP1 | DsWIVPLDNLTKDDLDEEEDtHL__________________ |
| O15067 | S530 | Sugiyama | PFAS KIAA0361 | PICsLHDQGAGGNGNVLKELsDPAGAIIytsRFQLGDPTLN |
| O15427 | S464 | Sugiyama | SLC16A3 MCT3 MCT4 | EHFLKAEPEKNGEVVHtPEtsV___________________ |
| O43390 | T134 | Sugiyama | HNRNPR HNRPR | KVQESTKGPDEAKIKALLERtGytLDVttGQRKYGGPPPDS |
| O43390 | T137 | Sugiyama | HNRNPR HNRPR | ESTKGPDEAKIKALLERtGytLDVttGQRKYGGPPPDSVYS |
| O43390 | Y136 | Sugiyama | HNRNPR HNRPR | QESTKGPDEAKIKALLERtGytLDVttGQRKYGGPPPDSVY |
| O43396 | T117 | Sugiyama | TXNL1 TRP32 TXL TXNL | VGLEEKIKQHLENDPGsNEDtDIPKGYMDLMPFINKAGCEC |
| O43615 | S94 | Sugiyama | TIMM44 MIMT44 TIM44 | NKEMKESIKKFRDEARRLEEsDVLQEARRKyKtIESETVRT |
| O43823 | T681 | Sugiyama | AKAP8 AKAP95 | ESAQTRVAPAPAAADAEVEQtDAEsKDAVPTE_________ |
| O43852 | T196 | Sugiyama | CALU | FtAFLHPEEyDyMKDIVVQEtMEDIDKNADGFIDLEEyIGD |
| O60220 | S96 | Sugiyama | TIMM8A DDP DDP1 TIM8A | FILNRLEQTQKSKPVFSEsLsD___________________ |
| O60231 | S107 | Sugiyama | DHX16 DBP2 DDX16 KIAA0577 PRP2 | ARALLEKNRSYRLLEDsEEssEEtVsRAGsSLQKKRKKRKH |
| O60271 | S813 | Sugiyama | SPAG9 HSS KIAA0516 MAPK8IP4 SYD1 HLC6 | LCIASVPGARETDYPAGEDLsEsGQVDKASLCGSMTSNSSA |
| O60361 | Y136 | Sugiyama | NME2P1 | SLRFKPEELVDYKSCAHDWVyE___________________ |
| O60506 | T131 | Sugiyama | SYNCRIP HNRPQ NSAP1 | KVADSSKGPDEAKIKALLERtGytLDVttGQRKYGGPPPDS |
| O60506 | T134 | Sugiyama | SYNCRIP HNRPQ NSAP1 | DSSKGPDEAKIKALLERtGytLDVttGQRKYGGPPPDSVYS |
| O60506 | Y133 | Sugiyama | SYNCRIP HNRPQ NSAP1 | ADSSKGPDEAKIKALLERtGytLDVttGQRKYGGPPPDSVY |
| O60664 | S148 | Sugiyama | PLIN3 M6PRBP1 TIP47 | KVsGAQEMVssAKDTVAtQLsEAVDATRGAVQSGVDKTKsV |
| O60664 | T145 | Sugiyama | PLIN3 M6PRBP1 TIP47 | VssKVsGAQEMVssAKDTVAtQLsEAVDATRGAVQSGVDKT |
| O60841 | S186 | Sugiyama | EIF5B IF2 KIAA0741 | EDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKKNQKN |
| O60841 | S66 | Sugiyama | EIF5B IF2 KIAA0741 | KEKKKQDFDEDDILKELEELsLEAQGIKADREtVAVKPTEN |
| O60927 | S74 | Sugiyama | PPP1R11 HCGV TCTE5 | GRRssKCCCIyEKPRAFGEsstEsDEEEEEGCGHtHCVRGH |
| O75400 | S938 | Sugiyama | PRPF40A FBP11 FLAF1 FNBP3 HIP10 HYPA HSPC225 | SPKKKtGKDsGNWDtsGsELsEGELEKRRRtLLEQLDDDQ_ |
| O75821 | S189 | Sugiyama | EIF3G EIF3S4 | CPYKDtLGPMQKELAEQLGLstGEKEKLPGELEPVQAtQNK |
| O75822 | S127 | Sugiyama | EIF3J EIF3S1 PRO0391 | VLtPEEQLADKLRLKKLQEEsDLELAKEtFGVNNAVyGIDA |
| O95218 | S188 | Sugiyama | ZRANB2 ZIS ZNF265 | KLDEDEDEDDADLsKyNLDAsEEEDsNKKKSNRRSRSKSRS |
| O95551 | T88 | GPS6|SIGNOR|EPSD|PSP | TDP2 EAP2 TTRAP AD-022 | ESALERRPETISEPKTyVDLtNEEtTDsttsKISPSEDTQQ |
| O95551 | T92 | GPS6|SIGNOR|EPSD|PSP | TDP2 EAP2 TTRAP AD-022 | ERRPETISEPKTyVDLtNEEtTDsttsKISPSEDTQQENGS |
| O95831 | S116 | Sugiyama | AIFM1 AIF PDCD8 | NERIsGLGLtPEQKQKKAALsAsEGEEVPQDKAPSHVPFLL |
| P00338 | T322 | Sugiyama | LDHA PIG19 | DLVKVTLtsEEEARLKKsADtLWGIQKELQF__________ |
| P00505 | S118 | Sugiyama | GOT2 KYAT4 | PIGGLAEFCKASAELALGENsEVLKSGRFVTVQTIsGtGAL |
| P00558 | S390 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | IIGGGDtAtCCAKWNtEDKVsHVstGGGAsLELLEGKVLPG |
| P00558 | S399 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | CCAKWNtEDKVsHVstGGGAsLELLEGKVLPGVDALsNI__ |
| P00558 | T376 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | MDEVVKAtsRGCItIIGGGDtAtCCAKWNtEDKVsHVstGG |
| P00558 | T378 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | EVVKAtsRGCItIIGGGDtAtCCAKWNtEDKVsHVstGGGA |
| P00558 | T394 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | GDtAtCCAKWNtEDKVsHVstGGGAsLELLEGKVLPGVDAL |
| P02786 | S151 | Sugiyama | TFRC | LsEKLDstDFTGtIKLLNENsyVPREAGsQKDENLALyVEN |
| P04075 | S17 | Sugiyama | ALDOA ALDA | ____MPyQyPALtPEQKKELsDIAHRIVAPGKGILAADEst |
| P04075 | S336 | Sugiyama | ALDOA ALDA | GKKENLKAAQEEYVKRALANsLACQGKytPsGQAGAAAsEs |
| P04075 | S354 | Sugiyama | ALDOA ALDA | ANsLACQGKytPsGQAGAAAsEsLFVsNHAy__________ |
| P04075 | S356 | Sugiyama | ALDOA ALDA | sLACQGKytPsGQAGAAAsEsLFVsNHAy____________ |
| P04075 | S36 | Sugiyama | ALDOA ALDA | LsDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENR |
| P04075 | T119 | Sugiyama | ALDOA ALDA | KsKGGVVGIKVDKGVVPLAGtNGEtttQGLDGLsERCAQYK |
| P04075 | T123 | Sugiyama | ALDOA ALDA | GVVGIKVDKGVVPLAGtNGEtttQGLDGLsERCAQYKKDGA |
| P04075 | T37 | Sugiyama | ALDOA ALDA | sDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRR |
| P04075 | T52 | Sugiyama | ALDOA ALDA | AADEstGsIAKRLQsIGtENtEENRRFyRQLLLtADDRVNP |
| P04083 | S189 | Sugiyama | ANXA1 ANX1 LPC1 | tsDtsGDFRNALLsLAKGDRsEDFGVNEDLADsDARALyEA |
| P04083 | S201 | Sugiyama | ANXA1 ANX1 LPC1 | LsLAKGDRsEDFGVNEDLADsDARALyEAGERRKGtDVNVF |
| P04083 | T169 | Sugiyama | ANXA1 ANX1 LPC1 | IRDINRVYREELKRDLAKDItsDtsGDFRNALLsLAKGDRs |
| P04406 | S241 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKV |
| P04406 | T246 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | GKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKVVKQAS |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P05198 | T284 | Sugiyama | EIF2S1 EIF2A | EKRGVFNVQMEPKVVtDtDEtELARQMERLERENAEVDGDD |
| P05386 | S101 | Sugiyama | RPLP1 RRP1 | APstAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD_______ |
| P05386 | S104 | Sugiyama | RPLP1 RRP1 | tAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD__________ |
| P05387 | S102 | Sugiyama | RPLP2 D11S2243E RPP2 | PAAGsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD_______ |
| P05387 | S105 | Sugiyama | RPLP2 D11S2243E RPP2 | GsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD__________ |
| P05388 | S304 | Sugiyama | RPLP0 | AttAAPAAAAAPAKVEAKEEsEEsDEDMGFGLFD_______ |
| P05388 | S307 | Sugiyama | RPLP0 | AAPAAAAAPAKVEAKEEsEEsDEDMGFGLFD__________ |
| P05455 | S83 | Sugiyama | SSB | TDFNVIVEALSKSKAELMEIsEDKTKIRRsPsKPLPEVTDE |
| P05787 | S291 | Sugiyama | KRT8 CYK8 | ANRsRAEAEsMyQIKyEELQsLAGKHGDDLRRTKTEISEMN |
| P06733 | S37 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | NPtVEVDLFtsKGLFRAAVPsGAstGIyEALELRDNDKtRY |
| P06733 | S40 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | VEVDLFtsKGLFRAAVPsGAstGIyEALELRDNDKtRYMGK |
| P06733 | T100 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | KKLNVtEQEKIDKLMIEMDGtENKsKFGANAILGVsLAVCK |
| P06733 | T205 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | GAEVyHNLKNVIKEKyGKDAtNVGDEGGFAPNILENKEGLE |
| P06733 | T41 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | EVDLFtsKGLFRAAVPsGAstGIyEALELRDNDKtRYMGKG |
| P07195 | T18 | Sugiyama | LDHB | ___MATLKEKLIAPVAEEEAtVPNNKITVVGVGQVGMACAI |
| P07195 | T323 | Sugiyama | LDHB | sVINQKLKDDEVAQLKKsADtLWDIQKDLKDL_________ |
| P07205 | S390 | Sugiyama | PGK2 PGKB | VIGGGDTATCCAKWNtEDKVsHVstGGGAsLELLEGKILPG |
| P07205 | S399 | Sugiyama | PGK2 PGKB | CCAKWNtEDKVsHVstGGGAsLELLEGKILPGVEALSNM__ |
| P07205 | T394 | Sugiyama | PGK2 PGKB | GDTATCCAKWNtEDKVsHVstGGGAsLELLEGKILPGVEAL |
| P07237 | S88 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | GKLKAEGSEIRLAKVDAtEEsDLAQQyGVRGyPtIKFFRNG |
| P07237 | T85 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | KAAGKLKAEGSEIRLAKVDAtEEsDLAQQyGVRGyPtIKFF |
| P07355 | S184 | Sugiyama | ANXA2 ANX2 ANX2L4 CAL1H LPC2D | sGDFRKLMVALAKGRRAEDGsVIDyELIDQDARDLyDAGVK |
| P07437 | T55 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | tyHGDsDLQLDRIsVyyNEAtGGKyVPRAILVDLEPGtMDs |
| P07737 | S30 | Sugiyama | PFN1 | NLMADGTCQDAAIVGYKDsPsVWAAVPGKtFVNITPAEVGV |
| P07737 | S85 | Sugiyama | PFN1 | tLGGQKCsVIRDsLLQDGEFsMDLRtKstGGAPTFNVtVtK |
| P07900 | S164 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | VAEKVTVITKHNDDEQyAWEssAGGsFtVRTDTGEPMGRGT |
| P07900 | S165 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | AEKVTVITKHNDDEQyAWEssAGGsFtVRTDTGEPMGRGTK |
| P07900 | S50 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | MSLIINtFySNKEIFLRELIsNssDALDKIRyEsLtDPsKL |
| P07900 | S52 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | LIINtFySNKEIFLRELIsNssDALDKIRyEsLtDPsKLDs |
| P07900 | S53 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | IINtFySNKEIFLRELIsNssDALDKIRyEsLtDPsKLDsG |
| P07900 | T195 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | DTGEPMGRGTKVILHLKEDQtEyLEERRIKEIVKKHSQFIG |
| P07900 | T305 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | IDQEELNKtKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLA |
| P07900 | Y309 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | ELNKtKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHF |
| P08195 | S598 | Sugiyama | SLC3A2 MDU1 | LQASDLPASASLPAKADLLLstQPGREEGsPLELERLKLEP |
| P08195 | T599 | Sugiyama | SLC3A2 MDU1 | QASDLPASASLPAKADLLLstQPGREEGsPLELERLKLEPH |
| P08238 | S159 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | VAEKVVVITKHNDDEQyAWEssAGGsFtVRADHGEPIGRGT |
| P08238 | S160 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | AEKVVVITKHNDDEQyAWEssAGGsFtVRADHGEPIGRGTK |
| P08238 | S45 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | MSLIINTFYSNKEIFLRELIsNAsDALDKIRyEsLtDPsKL |
| P08238 | S462 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | HEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQKs |
| P08238 | S48 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | IINTFYSNKEIFLRELIsNAsDALDKIRyEsLtDPsKLDsG |
| P08238 | T190 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | DHGEPIGRGTKVILHLKEDQtEyLEERRVKEVVKKHsQFIG |
| P08238 | T297 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | IDQEELNKtKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLA |
| P08238 | T467 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | NRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQKsIyyIt |
| P08238 | Y301 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | ELNKtKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHF |
| P08238 | Y457 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | LKLGIHEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMK |
| P08708 | S89 | Sugiyama | RPS17 RPS17L | ISIKLQEEERERRDNyVPEVsALDQEIIEVDPDtKEMLKLL |
| P08758 | T10 | Sugiyama | ANXA5 ANX5 ENX2 PP4 | ___________MAQVLRGtVtDFPGFDERADAEtLRKAMKG |
| P09104 | S37 | Sugiyama | ENO2 | NPtVEVDLyTAKGLFRAAVPsGAstGIyEALELRDGDKQRY |
| P09104 | T41 | Sugiyama | ENO2 | EVDLyTAKGLFRAAVPsGAstGIyEALELRDGDKQRYLGKG |
| P09382 | T58 | Sugiyama | LGALS1 | DsNNLCLHFNPRFNAHGDANtIVCNsKDGGAWGTEQREAVF |
| P09651 | S95 | Sugiyama | HNRNPA1 HNRPA1 | RPHKVDGRVVEPKRAVsREDsQRPGAHLtVKKIFVGGIKED |
| P0CG38 | S1068 | Sugiyama | POTEI | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P0CG38 | Y1062 | Sugiyama | POTEI | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCF_______ |
| P0CG39 | S1031 | Sugiyama | POTEJ | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P0CG39 | Y1025 | Sugiyama | POTEJ | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCF_______ |
| P10599 | T100 | Sugiyama | TXN TRDX TRX TRX1 | FKKGQKVGEFSGANKEKLEAtINELV_______________ |
| P10809 | S488 | Sugiyama | HSPD1 HSP60 | IKRTLKIPAMtIAKNAGVEGsLIVEKIMQSSsEVGYDAMAG |
| P10809 | S67 | Sugiyama | HSPD1 HSP60 | LADAVAVTMGPKGRtVIIEQsWGsPKVTKDGVtVAKsIDLK |
| P10809 | T105 | Sugiyama | HSPD1 HSP60 | DLKDKYKNIGAKLVQDVANNtNEEAGDGtttAtVLARSIAK |
| P11142 | T163 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | VVtVPAyFNDsQRQAtKDAGtIAGLNVLRIINEPtAAAIAy |
| P11142 | T226 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | DVSILTIEDGIFEVKstAGDtHLGGEDFDNRMVNHFIAEFK |
| P11142 | T45 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | KVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAMNPtN |
| P11142 | T47 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | EIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAMNPtNtV |
| P11142 | Y41 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P11940 | T191 | Sugiyama | PABPC1 PAB1 PABP PABP1 PABPC2 | GRFKSRKEREAELGARAKEFtNVyIKNFGEDMDDERLKDLF |
| P12004 | S261 | Sugiyama | PCNA | IADMGHLKyyLAPKIEDEEGs____________________ |
| P12956 | S27 | Sugiyama | XRCC6 G22P1 | YYKtEGDEEAEEEQEENLEAsGDyKYsGRDsLIFLVDASKA |
| P12956 | S560 | Sugiyama | XRCC6 G22P1 | VtKRKHDNEGSGSKRPKVEysEEELKTHISKGTLGKFTVPM |
| P13489 | S178 | Sugiyama | RNH1 PRI RNH | SCEPLASVLRAKPDFKELtVsNNDINEAGVRVLCQGLKDSP |
| P13489 | S290 | Sugiyama | RNH1 PRI RNH | AKGCGDLCRVLRAKESLKELsLAGNELGDEGARLLCETLLE |
| P13489 | T176 | Sugiyama | RNH1 PRI RNH | AASCEPLASVLRAKPDFKELtVsNNDINEAGVRVLCQGLKD |
| P13639 | S584 | Sugiyama | EEF2 EF2 | DHACIPIKKSDPVVsyREtVsEEsNVLCLsKsPNKHNRLyM |
| P13639 | S587 | Sugiyama | EEF2 EF2 | CIPIKKSDPVVsyREtVsEEsNVLCLsKsPNKHNRLyMKAR |
| P13667 | S379 | Sugiyama | PDIA4 ERP70 ERP72 | QPEKFQSKYEPRSHMMDVQGstQDsAIKDFVLKyALPLVGH |
| P13797 | S113 | Sugiyama | PLS3 | FRKAINRKEGICALGGTsELssEGtQHsysEEEKyAFVNWI |
| P13798 | S185 | Sugiyama | APEH D3F15S2 D3S48E DNF15S2 | VAEKKRPKAEsFFQTKALDVsAsDDEIARLKKPDQAIKGDQ |
| P13929 | S37 | Sugiyama | ENO3 | NPtVEVDLHtAKGRFRAAVPsGAstGIyEALELRDGDKGRY |
| P13929 | T41 | Sugiyama | ENO3 | EVDLHtAKGRFRAAVPsGAstGIyEALELRDGDKGRYLGKG |
| P14314 | T103 | Sugiyama | PRKCSH G19P1 | KPLyIPSNRVNDGVCDCCDGtDEyNsGVICENtCKEKGRKE |
| P14618 | S202 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | SLQVKQKGADFLVtEVENGGsLGsKKGVNLPGAAVDLPAVs |
| P14618 | T195 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | yVDDGLISLQVKQKGADFLVtEVENGGsLGsKKGVNLPGAA |
| P14618 | T409 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | IyHLQLFEELRRLAPITsDPtEAtAVGAVEAsFKCCsGAII |
| P14618 | T412 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | LQLFEELRRLAPITsDPtEAtAVGAVEAsFKCCsGAIIVLT |
| P14625 | S106 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | MKLIINSLYKNKEIFLRELIsNAsDALDKIRLISLTDENAL |
| P14625 | S109 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | IINSLYKNKEIFLRELIsNAsDALDKIRLISLTDENALSGN |
| P14625 | S306 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | TETVEEPMEEEEAAKEEKEEsDDEAAVEEEEEEKKPKTKKV |
| P14625 | S439 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | TDDFHDMMPKyLNFVKGVVDsDDLPLNVsREtLQQHKLLKV |
| P15311 | S535 | Sugiyama | EZR VIL2 | EKRITEAEKNERVQRQLLtLssELsQARDENKRTHNDIIHN |
| P15311 | S539 | Sugiyama | EZR VIL2 | TEAEKNERVQRQLLtLssELsQARDENKRTHNDIIHNENMR |
| P15311 | T533 | Sugiyama | EZR VIL2 | NEEKRITEAEKNERVQRQLLtLssELsQARDENKRTHNDII |
| P15531 | S122 | Sugiyama | NME1 NDPKA NM23 | GtIRGDFCIQVGRNIIHGsDsVEsAEKEIGLWFHPEELVDy |
| P17066 | T228 | Sugiyama | HSPA6 HSP70B' | DVSVLSIDAGVFEVKAtAGDtHLGGEDFDNRLVNHFMEEFR |
| P17066 | T47 | Sugiyama | HSPA6 HSP70B' | RVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAALNPHN |
| P17066 | T49 | Sugiyama | HSPA6 HSP70B' | EILANDQGNRTtPsyVAFtDtERLVGDAAKsQAALNPHNtV |
| P17096 | S103 | Sugiyama | HMGA1 HMGIY | PRGRPKKLEKEEEEGIsQEssEEEQ________________ |
| P17812 | S578 | Sugiyama | CTPS1 CTPS | GCRLsPRDtysDRsGsssPDsEItELKFPsINHD_______ |
| P17987 | S551 | Sugiyama | TCP1 CCT1 CCTA | IKLHPESKDDKHGsyEDAVHsGALND_______________ |
| P18669 | T146 | Sugiyama | PGAM1 PGAMA CDABP0006 | MEPDHPFysNIsKDRRyADLtEDQLPsCEsLKDtIARALPF |
| P19338 | S619 | Sugiyama | NCL | RIVTDRETGssKGFGFVDFNsEEDAKAAKEAMEDGEIDGNK |
| P20042 | S67 | Sugiyama | EIF2S2 EIF2B | EPtEDKDLEADEEDTRKKDAsDDLDDLNFFNQKKKKKKTKK |
| P20042 | T111 | Sugiyama | EIF2S2 EIF2B | IDEAEEGVKDLKIEsDVQEPtEPEDDLDIMLGNKKKKKKNV |
| P20618 | Y158 | Sugiyama | PSMB1 PSC5 | IGGLDEEGKGAVysFDPVGsyQRDsFKAGGSASAMLQPLLD |
| P20810 | S373 | Sugiyama | CAST | LPEPEEKPKPRsEsELIDELsEDFDRsECKEKPSKPTEKTE |
| P22314 | S46 | Sugiyama | UBA1 A1S9T UBE1 | AQsVLsEVPSVPTNGMAKNGsEADIDEGLysRQLyVLGHEA |
| P22392 | Y151 | Sugiyama | NME2 NM23B | SLWFKPEELVDyKSCAHDWVyE___________________ |
| P23588 | S207 | Sugiyama | EIF4B | DRNRDsDKtDTDWRARPAtDsFDDyPPRRGDDsFGDKYRDR |
| P24386 | S652 | Sugiyama | CHM REP1 TCD | PEANSETFKESTNLGNLEEssE___________________ |
| P25705 | S52 | Sugiyama | ATP5F1A ATP5A ATP5A1 ATP5AL2 ATPM | AARNFHASNTHLQKtGtAEMssILEERILGADtsVDLEETG |
| P25705 | S53 | Sugiyama | ATP5F1A ATP5A ATP5A1 ATP5AL2 ATPM | ARNFHASNTHLQKtGtAEMssILEERILGADtsVDLEETGR |
| P25705 | S65 | Sugiyama | ATP5F1A ATP5A ATP5A1 ATP5AL2 ATPM | KtGtAEMssILEERILGADtsVDLEETGRVLsIGDGIARVH |
| P25786 | T11 | Sugiyama | PSMA1 HC2 NU PROS30 PSC2 | __________MFRNQyDNDVtVWsPQGRIHQIEYAMEAVKQ |
| P25788 | S243 | Sugiyama | PSMA3 HC8 PSC8 | GRHEIVPKDIREEAEKyAKEsLKEEDEsDDDNM________ |
| P25788 | S250 | Sugiyama | PSMA3 HC8 PSC8 | KDIREEAEKyAKEsLKEEDEsDDDNM_______________ |
| P26038 | S576 | Sugiyama | MSN | YKtLRQIRQGNTKQRIDEFEsM___________________ |
| P26639 | S522 | Sugiyama | TARS1 TARS | PEKFLGDIEVWDQAEKQLENsLNEFGEKWELNsGDGAFyGP |
| P27348 | S145 | Sugiyama | YWHAQ | YFRyLAEVACGDDRKQtIDNsQGAyQEAFDIsKKEMQPTHP |
| P27348 | S37 | Sugiyama | YWHAQ | ERyDDMAtCMKAVtEQGAELsNEERNLLsVAyKNVVGGRRS |
| P27348 | S45 | Sugiyama | YWHAQ | CMKAVtEQGAELsNEERNLLsVAyKNVVGGRRSAWRVIsSI |
| P27348 | T141 | Sugiyama | YWHAQ | MKGDYFRyLAEVACGDDRKQtIDNsQGAyQEAFDIsKKEMQ |
| P27816 | S1151 | Sugiyama | MAP4 | LSGGGDQREAQtLDsQIQEtsI___________________ |
| P27816 | S643 | Sugiyama | MAP4 | IsPEtVTGtGKKCsLPAEEDsVLEKLGERKPCNsQPSELSS |
| P29692 | S162 | Sugiyama | EEF1D EF1D | AKKPAtPAEDDEDDDIDLFGsDNEEEDKEAAQLREERLRQY |
| P29692 | S64 | Sugiyama | EEF1D EF1D | sVILRDIARARENIQKsLAGssGPGAssGtsGDHGELVVRI |
| P29692 | S65 | Sugiyama | EEF1D EF1D | VILRDIARARENIQKsLAGssGPGAssGtsGDHGELVVRIA |
| P29692 | S70 | Sugiyama | EEF1D EF1D | IARARENIQKsLAGssGPGAssGtsGDHGELVVRIAsLEVE |
| P30050 | S157 | Sugiyama | RPL12 | QsVGCNVDGRHPHDIIDDINsGAVECPAs____________ |
| P30101 | T485 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | KKyEGGRELsDFIsyLQREAtNPPVIQEEKPKKKKKAQEDL |
| P31153 | S38 | Sugiyama | MAT2A AMS2 MATA2 | FLFTSESVGEGHPDKICDQIsDAVLDAHLQQDPDAKVACET |
| P31946 | S39 | Sugiyama | YWHAB | ERyDDMAAAMKAVtEQGHELsNEERNLLsVAyKNVVGARRS |
| P31946 | S47 | Sugiyama | YWHAB | AMKAVtEQGHELsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P31947 | S45 | Sugiyama | SFN HME1 | FMKGAVEKGEELsCEERNLLsVAyKNVVGGQRAAWRVLSsI |
| P31948 | S459 | Sugiyama | STIP1 | EAMKDytKAMDVYQKALDLDssCKEAADGYQRCMMAQyNRH |
| P31948 | S460 | Sugiyama | STIP1 | AMKDytKAMDVYQKALDLDssCKEAADGYQRCMMAQyNRHD |
| P34931 | T228 | Sugiyama | HSPA1L | DVSILTIDDGIFEVKAtAGDtHLGGEDFDNRLVsHFVEEFK |
| P34931 | T47 | Sugiyama | HSPA1L | KVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAMNPQN |
| P34931 | T49 | Sugiyama | HSPA1L | EIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAMNPQNTV |
| P34931 | Y43 | Sugiyama | HSPA1L | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P34932 | S31 | Sugiyama | HSPA4 APG2 HSPH2 | QSCYVAVARAGGIETIANEysDRCtPACIsFGPKNRSIGAA |
| P34932 | S415 | Sugiyama | HSPA4 APG2 HSPH2 | TDVVPYPISLRWNsPAEEGssDCEVFSKNHAAPFSKVLTFy |
| P35221 | S641 | Sugiyama | CTNNA1 | GIRDIRKAVLMIRtPEELDDsDFEtEDFDVRsRtsVQtEDD |
| P35269 | S218 | Sugiyama | GTF2F1 RAP74 | GRRKASELRIHDLEDDLEMssDAsDAsGEEGGRVPKAKKKA |
| P35579 | T1904 | Sugiyama | MYH9 | EEAQRANAsRRKLQRELEDAtEtADAMNREVssLKNKLRRG |
| P35579 | T1906 | Sugiyama | MYH9 | AQRANAsRRKLQRELEDAtEtADAMNREVssLKNKLRRGDL |
| P35613 | S279 | Sugiyama | BSG UNQ6505/PRO21383 | TDSEDKALMNGSESRFFVsssQGRSELHIENLNMEADPGQy |
| P35659 | S231 | Sugiyama | DEK | SGMARKAKRTKCPEILsDEsssDEDEKKNKEEssDDEDKEs |
| P35659 | S306 | Sugiyama | DEK | DSSTTKKNQNSSKKEsEsEDssDDEPLIKKLKKPPTDEELK |
| P36871 | S477 | Sugiyama | PGM1 | KQFSANDKVYtVEKADNFEysDPVDGsIsRNQGLRLIFTDG |
| P36896 | S168 | Sugiyama | ACVR1B ACVRLK4 ALK4 | VINYHQRVYHNRQRLDMEDPsCEMCLsKDKTLQDLVYDLST |
| P36896 | S174 | Sugiyama | ACVR1B ACVRLK4 ALK4 | RVYHNRQRLDMEDPsCEMCLsKDKTLQDLVYDLSTSGSGSG |
| P36896 | S498 | Sugiyama | ACVR1B ACVRLK4 ALK4 | YANGAARLTALRIKKTLSQLsVQEDVKI_____________ |
| P36896 | T364 | Sugiyama | ACVR1B ACVRLK4 ALK4 | KKNGMCAIADLGLAVRHDAVtDtIDIAPNQRVGTKRyMAPE |
| P36896 | T366 | Sugiyama | ACVR1B ACVRLK4 ALK4 | NGMCAIADLGLAVRHDAVtDtIDIAPNQRVGTKRyMAPEVL |
| P36896 | T389 | Sugiyama | ACVR1B ACVRLK4 ALK4 | IAPNQRVGTKRyMAPEVLDEtINMKHFDSFKCADIYALGLV |
| P37802 | S163 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | LFsGDPNWFPKKSKENPRNFsDNQLQEGKNVIGLQMGtNRG |
| P37802 | S185 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | NQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL______ |
| P37802 | T190 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | GKNVIGLQMGtNRGAsQAGMtGyGMPRQIL___________ |
| P38646 | T398 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | SDIGEVILVGGMTRMPKVQQtVQDLFGRAPsKAVNPDEAVA |
| P38646 | T480 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | RNTTIPTKKSQVFstAADGQtQVEIKVCQGEREMAGDNKLL |
| P41091 | T21 | Sugiyama | EIF2S3 EIF2G | MAGGEAGVtLGQPHLsRQDLttLDVtKLTPLSHEVISRQAt |
| P41227 | S216 | Sugiyama | NAA10 ARD1 ARD1A TE2 | EEKGLAAEDsGGDsKDLsEVsEtTEstDVKDssEAsDsAs_ |
| P43121 | T299 | Sugiyama | MCAM MUC18 | PPHFSISKQNPstREAEEEttNDNGVLVLEPARKEHSGRYE |
| P45974 | S783 | Sugiyama | USP5 ISOT | IDDLDAEAAMDISEGRsAADsIsEsVPVGPKVRDGPGKYQL |
| P45974 | S785 | Sugiyama | USP5 ISOT | DLDAEAAMDISEGRsAADsIsEsVPVGPKVRDGPGKYQLFA |
| P46063 | S53 | Sugiyama | RECQL RECQ1 RECQL1 | QELIQKKKVLTKKIKQCLEDsDAGAsNEyDssPAAWNKEDF |
| P46777 | S172 | Sugiyama | RPL5 MSTP030 | RTTTGNKVFGALKGAVDGGLsIPHstKRFPGyDsEsKEFNA |
| P48643 | S539 | Sugiyama | CCT5 CCTE KIAA0098 | LATQMVRMILKIDDIRKPGEsEE__________________ |
| P48741 | T228 | Sugiyama | HSPA7 HSP70B | DVSVLSIDAGVFEVKAtAGDtHLGGEDFDNRLVNHFMEEFR |
| P48741 | T47 | Sugiyama | HSPA7 HSP70B | RVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAALNPHN |
| P48741 | T49 | Sugiyama | HSPA7 HSP70B | EILANDQGNRTtPsyVAFtDtERLVGDAAKsQAALNPHNtV |
| P49321 | S432 | Sugiyama | NASP | EKVRAKLVPsQEEtKLsVEEsEAAGDGVDTKVAQGAtEKsP |
| P49327 | S2198 | Sugiyama | FASN FAS | EVRQLTLRKLQELSSKADEAsELACPtPKEDGLAQQQtQLN |
| P49589 | S305 | Sugiyama | CARS1 CARS | KLVPEAVGDQKALQEGEGDLsIsADRLsEKRSPNDFALWKA |
| P49589 | S307 | Sugiyama | CARS1 CARS | VPEAVGDQKALQEGEGDLsIsADRLsEKRSPNDFALWKASK |
| P50502 | S79 | Sugiyama | ST13 AAG2 FAM10A1 HIP SNC6 | KPDSKKVEEDLKADEPssEEsDLEIDKEGVIEPDTDAPQEM |
| P53999 | S118 | Sugiyama | SUB1 PC4 RPO2TC1 | PGRKGIsLNPEQWsQLKEQIsDIDDAVRKL___________ |
| P54105 | S102 | Sugiyama | CLNS1A CLCI ICLN | VNAKFEEEsKEPVADEEEEDsDDDVEPITEFRFVPSDKSAL |
| P54578 | S492 | Sugiyama | USP14 TGT | WHIAYVLLYGPRRVEIMEEEsEQ__________________ |
| P54652 | T229 | Sugiyama | HSPA2 | DVSILTIEDGIFEVKstAGDtHLGGEDFDNRMVSHLAEEFK |
| P54652 | T46 | Sugiyama | HSPA2 | KVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAMNPTN |
| P54652 | T48 | Sugiyama | HSPA2 | EIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAMNPTNTI |
| P54652 | Y42 | Sugiyama | HSPA2 | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P55060 | S366 | Sugiyama | CSE1L CAS XPO2 | KVIVPNMEFRAADEEAFEDNsEEyIRRDLEGsDIDTRRRAA |
| P57721 | S82 | Sugiyama | PCBP3 PCBP3-OT1 PCBP3OT | GKKGETVKKMREESGARINIsEGNCPERIVTITGPTDAIFK |
| P60174 | T38 | Sugiyama | TPI1 TPI | RKQsLGELIGtLNAAKVPADtEVVCAPPtAyIDFARQKLDP |
| P60174 | T46 | Sugiyama | TPI1 TPI | IGtLNAAKVPADtEVVCAPPtAyIDFARQKLDPKIAVAAQN |
| P60228 | S442 | Sugiyama | EIF3E EIF3S6 INT6 | IEKKLNQNSRSEAPNWAtQDsGFy_________________ |
| P60660 | T85 | Sugiyama | MYL6 | LDFEHFLPMLQTVAKNKDQGtyEDyVEGLRVFDKEGNGtVM |
| P60709 | S199 | Sugiyama | ACTB | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P60709 | S239 | Sugiyama | ACTB | VALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P60709 | S323 | Sugiyama | ACTB | ttMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGG |
| P60709 | S368 | Sugiyama | ACTB | sLstFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P60709 | S52 | Sugiyama | ACTB | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P60709 | T106 | Sugiyama | ACTB | WHHtFyNELRVAPEEHPVLLtEAPLNPKANREKMTQIMFET |
| P60709 | T303 | Sugiyama | ACTB | MKCDVDIRKDLyANtVLsGGttMyPGIADRMQKEItALAPs |
| P60709 | T304 | Sugiyama | ACTB | KCDVDIRKDLyANtVLsGGttMyPGIADRMQKEItALAPst |
| P60709 | T318 | Sugiyama | ACTB | VLsGGttMyPGIADRMQKEItALAPstMKIKIIAPPERKYs |
| P60709 | Y240 | Sugiyama | ACTB | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P60709 | Y362 | Sugiyama | ACTB | GGsILAsLstFQQMWISKQEyDEsGPsIVHRKCF_______ |
| P60709 | Y53 | Sugiyama | ACTB | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIEH |
| P61247 | S236 | Sugiyama | RPS3A FTE1 MFTL | KMLKKPKFELGKLMELHGEGsssGKAtGDEtGAKVERADGy |
| P61247 | Y256 | Sugiyama | RPS3A FTE1 MFTL | sssGKAtGDEtGAKVERADGyEPPVQEsV____________ |
| P61604 | S21 | Sugiyama | HSPE1 | MAGQAFRKFLPLFDRVLVERsAAETVTKGGIMLPEKSQGKV |
| P61916 | S29 | Sugiyama | NPC2 HE1 | LLLALSTAAQAEPVQFKDCGsVDGVIKEVNVsPCPtQPCQL |
| P61978 | S75 | Sugiyama | HNRNPK HNRPK | GAVIGKGGKNIKALRtDyNAsVsVPDssGPERILsISADIE |
| P61978 | S77 | Sugiyama | HNRNPK HNRPK | VIGKGGKNIKALRtDyNAsVsVPDssGPERILsISADIETI |
| P61981 | S46 | Sugiyama | YWHAG | AMKNVtELNEPLsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P61981 | T31 | Sugiyama | YWHAG | ARLAEQAERyDDMAAAMKNVtELNEPLsNEERNLLsVAyKN |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62258 | S148 | Sugiyama | YWHAE | YHRyLAEFAtGNDRKEAAENsLVAyKAAsDIAMtELPPTHP |
| P62258 | S46 | Sugiyama | YWHAE | SMKKVAGMDVELTVEERNLLsVAyKNVIGARRASWRIIssI |
| P62280 | T54 | Sugiyama | RPS11 | PRYYKNIGLGFKtPKEAIEGtyIDKKCPFTGNVsIRGRILs |
| P62736 | S241 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | VALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P62736 | S325 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P62736 | S54 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P62736 | T320 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | VLSGGtTMYPGIADRMQKEItALAPstMKIKIIAPPERKYS |
| P62736 | Y242 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P62736 | Y55 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P62942 | T7 | Sugiyama | FKBP1A FKBP1 FKBP12 | ______________MGVQVEtIsPGDGRtFPKRGQtCVVHy |
| P63104 | S145 | Sugiyama | YWHAZ | YYRyLAEVAAGDDKKGIVDQsQQAyQEAFEIsKKEMQPTHP |
| P63104 | S37 | Sugiyama | YWHAZ | ERyDDMAACMKsVtEQGAELsNEERNLLsVAyKNVVGARRs |
| P63104 | S45 | Sugiyama | YWHAZ | CMKsVtEQGAELsNEERNLLsVAyKNVVGARRssWRVVssI |
| P63104 | T232 | Sugiyama | YWHAZ | KDstLIMQLLRDNLtLWtsDtQGDEAEAGEGGEN_______ |
| P63104 | T30 | Sugiyama | YWHAZ | AKLAEQAERyDDMAACMKsVtEQGAELsNEERNLLsVAyKN |
| P63146 | S148 | Sugiyama | UBE2B RAD6B UBCH1 | QLYQENKREYEKRVsAIVEQsWNDS________________ |
| P63167 | S14 | Sugiyama | DYNLL1 DLC1 DNCL1 DNCLC1 HDLC1 | _______MCDRKAVIKNADMsEEMQQDsVECAtQALEKYNI |
| P63261 | S199 | Sugiyama | ACTG1 ACTG | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P63261 | S239 | Sugiyama | ACTG1 ACTG | VALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P63261 | S323 | Sugiyama | ACTG1 ACTG | ttMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGG |
| P63261 | S368 | Sugiyama | ACTG1 ACTG | sLstFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P63261 | S52 | Sugiyama | ACTG1 ACTG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P63261 | T106 | Sugiyama | ACTG1 ACTG | WHHtFyNELRVAPEEHPVLLtEAPLNPKANREKMTQIMFET |
| P63261 | T303 | Sugiyama | ACTG1 ACTG | MKCDVDIRKDLyANtVLsGGttMyPGIADRMQKEItALAPs |
| P63261 | T304 | Sugiyama | ACTG1 ACTG | KCDVDIRKDLyANtVLsGGttMyPGIADRMQKEItALAPst |
| P63261 | T318 | Sugiyama | ACTG1 ACTG | VLsGGttMyPGIADRMQKEItALAPstMKIKIIAPPERKYs |
| P63261 | Y240 | Sugiyama | ACTG1 ACTG | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P63261 | Y362 | Sugiyama | ACTG1 ACTG | GGsILAsLstFQQMWISKQEyDEsGPsIVHRKCF_______ |
| P63261 | Y53 | Sugiyama | ACTG1 ACTG | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIEH |
| P63267 | S240 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | VALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P63267 | S324 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P63267 | S53 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P63267 | T319 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | VLSGGtTMYPGIADRMQKEItALAPstMKIKIIAPPERKYS |
| P63267 | Y241 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P63267 | Y54 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P67809 | S314 | Sugiyama | YBX1 NSEP1 YB1 | NPKPQDGKETKAADPPAENssAPEAEQGGAE__________ |
| P68032 | S241 | Sugiyama | ACTC1 ACTC | VALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P68032 | S325 | Sugiyama | ACTC1 ACTC | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P68032 | S54 | Sugiyama | ACTC1 ACTC | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68032 | T320 | Sugiyama | ACTC1 ACTC | VLSGGtTMYPGIADRMQKEItALAPstMKIKIIAPPERKYS |
| P68032 | Y242 | Sugiyama | ACTC1 ACTC | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68032 | Y55 | Sugiyama | ACTC1 ACTC | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P68133 | S241 | Sugiyama | ACTA1 ACTA | VALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P68133 | S325 | Sugiyama | ACTA1 ACTA | TTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P68133 | S54 | Sugiyama | ACTA1 ACTA | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68133 | T320 | Sugiyama | ACTA1 ACTA | VMSGGTTMYPGIADRMQKEItALAPstMKIKIIAPPERKYS |
| P68133 | Y242 | Sugiyama | ACTA1 ACTA | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68133 | Y55 | Sugiyama | ACTA1 ACTA | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P68363 | S439 | Sugiyama | TUBA1B | SEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy________ |
| P68363 | T73 | Sugiyama | TUBA1B | FsEtGAGKHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLI |
| P68363 | T80 | Sugiyama | TUBA1B | KHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAA |
| P68363 | Y432 | Sugiyama | TUBA1B | GMEEGEFSEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy_ |
| P68363 | Y451 | Sugiyama | TUBA1B | DyEEVGVDsVEGEGEEEGEEy____________________ |
| P84098 | T29 | Sugiyama | RPL19 | RLAssVLRCGKKKVWLDPNEtNEIANANsRQQIRKLIKDGL |
| Q00341 | S35 | Sugiyama | HDLBP HBP VGL | HRSGLVPQQIKVAtLNsEEEsDPPtyKDAFPPLPEKAACLE |
| Q00839 | Y260 | Sugiyama | HNRNPU C1orf199 HNRPU SAFA U21.1 | GDKKRGVKRPREDHGRGyFEyIEENKysRAKsPQPPVEEED |
| Q01105 | S161 | Sugiyama | SET | FDENPyFENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTK |
| Q04637 | S1430 | Sugiyama | EIF4G1 EIF4F EIF4G EIF4GI | GQDIGAFVAEQKVEyTLGEEsEAPGQRALPsEELNRQLEKL |
| Q04917 | S46 | Sugiyama | YWHAH YWHA1 | AMKAVtELNEPLsNEDRNLLsVAyKNVVGARRSsWRVIsSI |
| Q08J23 | T733 | Sugiyama | NSUN2 SAKI TRM4 | EGVILtNEsAAstGQPDNDVtEGQRAGEPNsPDAEEANsPD |
| Q12792 | T348 | Sugiyama | TWF1 PTK9 | GPAGKRGIRRLIRGPAEtEAttD__________________ |
| Q12906 | T300 | Sugiyama | ILF3 DRBF MPHOSPH4 NF90 | ASGIVMPDGSGIYDPCEKEAtDAIGHLDRQQREDItQsAQH |
| Q12952 | S174 | Sugiyama | FOXL1 FKHL11 FREAC7 | AKRPRAETHQRSAEAQPEAGsGAGGSGPAISRLQAAPAGPS |
| Q13155 | S48 | Sugiyama | AIMP2 JTV1 PRO0992 | PNVHGRSyGPAPGAGHVQEEsNLsLQALESRQDDILKRLYE |
| Q13263 | S479 | Sugiyama | TRIM28 KAP1 RNF96 TIF1B | ssAEPHVsGVKRsRsGEGEVsGLMRKVPRVsLERLDLDLtA |
| Q13283 | S149 | Sugiyama | G3BP1 G3BP | DIFRyQDEVFGGFVtEPQEEsEEEVEEPEERQQtPEVVPDD |
| Q13283 | T241 | Sugiyama | G3BP1 G3BP | ETAPEDAQKsssPAPADIAQtVQEDLRtFsWAsVtsKNLPP |
| Q13310 | T191 | Sugiyama | PABPC4 APP1 PABP4 | GRFKSRKEREAELGAKAKEFtNVyIKNFGEEVDDEsLKELF |
| Q13371 | S25 | Sugiyama | PDCL PHLOP1 PhLP1 | DDKLLGEKLQyyysssEDEDsDHEDKDRGRCAPAsssVPAE |
| Q13404 | S146 | Sugiyama | UBE2V1 CROC1 UBE2V UEV1 P/OKcl.19 | RLMMSKENMKLPQPPEGQCysN___________________ |
| Q13428 | S765 | Sugiyama | TCOF1 | GKTGPTVTQVKAEKQEDsEssEEEsDSEEAAAsPAQVKTSV |
| Q13428 | S88 | Sugiyama | TCOF1 | DAALQAKKTRVsDPIstsEssEEEEEAEAETAKAtPRLAst |
| Q13442 | S60 | Sugiyama | PDAP1 HASPP28 | QKEGGDGAAGDPKKEKKsLDsDEsEDEEDDyQQKRKGVEGL |
| Q13442 | S63 | Sugiyama | PDAP1 HASPP28 | GGDGAAGDPKKEKKsLDsDEsEDEEDDyQQKRKGVEGLIDI |
| Q13501 | S276 | Sugiyama | SQSTM1 ORCA OSIL | DIDVEHGGKRsRLtPVsPEssstEEKsssQPssCCsDPsKP |
| Q13501 | T278 | Sugiyama | SQSTM1 ORCA OSIL | DVEHGGKRsRLtPVsPEssstEEKsssQPssCCsDPsKPGG |
| Q13541 | S112 | Sugiyama | EIF4EBP1 | EAsQsHLRNsPEDKRAGGEEsQFEMDI______________ |
| Q13547 | S421 | Sugiyama | HDAC1 RPD3L1 | PDKRIsICssDKRIACEEEFsDsEEEGEGGRKNsSNFKKAK |
| Q13610 | S57 | Sugiyama | PWP1 | AEAKEKLQEEGGGsDEEEtGsPsEDGMQsARTQARPREPLE |
| Q13610 | T55 | Sugiyama | PWP1 | LIAEAKEKLQEEGGGsDEEEtGsPsEDGMQsARTQARPREP |
| Q13765 | S132 | Sugiyama | NACA HSD48 | YKSPAsDtyIVFGEAKIEDLsQQAQLAAAEKFKVQGEAVsN |
| Q13765 | T119 | Sugiyama | NACA HSD48 | SKNILFVITKPDVYKSPAsDtyIVFGEAKIEDLsQQAQLAA |
| Q14152 | S1256 | Sugiyama | EIF3A EIF3S10 KIAA0139 | EDRFRRPRDEGGWRRGPAEEsssWRDssRRDDRDRDDRRRE |
| Q14257 | T137 | Sugiyama | RCN2 ERC55 | VTWDEyNIQMyDRVIDFDENtALDDAEEEsFRKLHLKDKKR |
| Q14568 | S164 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | VAEKVTVITKHNDDEQyAWEssAGGsFtVRTDTGERMGRGT |
| Q14568 | S165 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | AEKVTVITKHNDDEQyAWEssAGGsFtVRTDTGERMGRGTK |
| Q14568 | S50 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | MSLIINTFYSNKEIFLRELIsNssDALDKIWYESLTDPSKL |
| Q14568 | S52 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | LIINTFYSNKEIFLRELIsNssDALDKIWYESLTDPSKLDS |
| Q14568 | S53 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | IINTFYSNKEIFLRELIsNssDALDKIWYESLTDPSKLDSG |
| Q14677 | S164 | Sugiyama | CLINT1 ENTH EPN4 EPNR KIAA0171 | RLREERKKAKKNKDKyVGVssDsVGGFRysERYDPEPKSKW |
| Q15080 | S67 | Sugiyama | NCF4 SH3PXD4 | TKGGSKYLIYRRYRQFHALQsKLEERFGPDSKSSALACTLP |
| Q15084 | T166 | Sugiyama | PDIA6 ERP5 P5 TXNDC7 | YSSGKQGRSDsSSKKDVIELtDDsFDKNVLDSEDVWMVEFY |
| Q15185 | S113 | Sugiyama | PTGES3 P23 TEBP | RAKLNWLsVDFNNWKDWEDDsDEDMsNFDRFSEMMNNMGGD |
| Q15185 | S118 | Sugiyama | PTGES3 P23 TEBP | WLsVDFNNWKDWEDDsDEDMsNFDRFSEMMNNMGGDEDVDL |
| Q15365 | S50 | Sugiyama | PCBP1 | GKKGESVKRIREEsGARINIsEGNCPERIItLTGPTNAIFK |
| Q15366 | S50 | Sugiyama | PCBP2 | GKKGESVKKMREESGARINIsEGNCPERIITLAGPTNAIFK |
| Q15459 | S690 | Sugiyama | SF3A1 SAP114 | VHPPPPMEDEPTSKKLKTEDsLMPEEEFLRRNKGPVSIKVQ |
| Q15527 | T190 | Sugiyama | SURF2 | LYPPELFTRKDLGstEDGDGtDDFLtDKEDEKAKPPREKAT |
| Q15796 | S464 | iPTMNet | SMAD2 MADH2 MADR2 | GPLQWLDKVLTQMGsPsVRCssMs_________________ |
| Q15796 | S465 | iPTMNet | SMAD2 MADH2 MADR2 | PLQWLDKVLTQMGsPsVRCssMs__________________ |
| Q15796 | S467 | iPTMNet | SMAD2 MADH2 MADR2 | QWLDKVLTQMGsPsVRCssMs____________________ |
| Q15819 | T142 | Sugiyama | UBE2V2 MMS2 UEV2 | LRRLMMSKENMKLPQPPEGQtyNN_________________ |
| Q16576 | T10 | Sugiyama | RBBP7 RBAP46 | ___________MAsKEMFEDtVEERVINEEYKIWKKNTPFL |
| Q2VIR3 | T21 | Sugiyama | EIF2S3B | MAGGEAGVtLGQPHLsRQDLttLDVtKLTPLSHEVISRQAt |
| Q32P51 | S95 | Sugiyama | HNRNPA1L2 HNRNPA1L | TPHKVDGRVVEPKRAVsREDsQRPGAHLtVKKIFVGGIKED |
| Q562R1 | S240 | Sugiyama | ACTBL2 | VALDFEQEMVRAAAssSPERsyELPDGQVItIGNERFRCPE |
| Q562R1 | Y241 | Sugiyama | ACTBL2 | ALDFEQEMVRAAAssSPERsyELPDGQVItIGNERFRCPEA |
| Q58FF6 | T165 | Sugiyama | HSP90AB4P | DHGEPIDRDTKVILHLKEDQtEyLEERWVKEVVKKHPQFIG |
| Q58FF7 | T169 | Sugiyama | HSP90AB3P HSP90BC | DHGEPIGRGTKVILHLKEDQtEyLEERRVKEVVKKHsQFIG |
| Q6PKG0 | S631 | Sugiyama | LARP1 KIAA0731 LARP | EEMEQMDGRKNtFtAWsDEEsDyEIDDRDVNKILIVtQtPH |
| Q6S8J3 | S1068 | Sugiyama | POTEE A26C1A POTE2 | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| Q6S8J3 | S939 | Sugiyama | POTEE A26C1A POTE2 | VALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| Q6S8J3 | Y1062 | Sugiyama | POTEE A26C1A POTE2 | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCF_______ |
| Q6S8J3 | Y940 | Sugiyama | POTEE A26C1A POTE2 | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| Q71U36 | S439 | Sugiyama | TUBA1A TUBA3 | SEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy________ |
| Q71U36 | T73 | Sugiyama | TUBA1A TUBA3 | FsEtGAGKHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLI |
| Q71U36 | T80 | Sugiyama | TUBA1A TUBA3 | KHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAA |
| Q71U36 | Y432 | Sugiyama | TUBA1A TUBA3 | GMEEGEFSEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy_ |
| Q71U36 | Y451 | Sugiyama | TUBA1A TUBA3 | DyEEVGVDsVEGEGEEEGEEy____________________ |
| Q7Z3K3 | S28 | Sugiyama | POGZ KIAA0461 SUHW5 ZNF280E ZNF635 Nbla00003 | MECEEEELEPWQKISDVIEDsVVEDyNsVDKTTTVSVSQQP |
| Q7Z417 | S652 | Sugiyama | NUFIP2 KIAA1321 PIG1 | NtLLGsAKEQRYQRGLERNDsWGsFDLRAAIVYHTKEMEsI |
| Q86TG7 | S10 | Sugiyama | PEG10 EDR KIAA1051e MAR2 MART2 MEF3L1 RGAG3 | ___________MTERRRDELsEEINNLREKVMKQSEENNNL |
| Q8NE71 | S595 | Sugiyama | ABCF1 ABC50 | TKEALTRKQQKCRRKNQDEEsQEAPELLKRPKEYTVRFTFP |
| Q8NEM2 | S42 | Sugiyama | SHCBP1 | GWAVEQELASLEKGLFQDEDsCsDCsYRDKPGssLQSFMPE |
| Q8NHW5 | S304 | Sugiyama | RPLP0P6 | DTTAAPAAAAAPAKVEAKEEsEEsDEDMGFGLFD_______ |
| Q8NHW5 | S307 | Sugiyama | RPLP0P6 | AAPAAAAAPAKVEAKEEsEEsDEDMGFGLFD__________ |
| Q8TAM6 | S280 | Sugiyama | ERMN KIAA1189 | TISYRKIRKGNTKQRIDEFEsMMHL________________ |
| Q8WU90 | S231 | Sugiyama | ZC3H15 DFRP1 LEREPO4 HSPC303 HT010 MSTP012 PP730 | LPPGFVLKKDKKKEEKEDEIsLEDLIERERSALGPNVTKIT |
| Q8WUM4 | T464 | Sugiyama | PDCD6IP AIP1 ALIX KIAA1375 | LQRNREILDEsLRLLDEEEAtDNDLRAKFKERWQRtPSNEL |
| Q92769 | S422 | Sugiyama | HDAC2 | PDKRIsIRAsDKRIACDEEFsDsEDEGEGGRRNVADHKKGA |
| Q92882 | S213 | Sugiyama | OSTF1 | QGTDAVRtLsNAEDyLDDEDsD___________________ |
| Q96C86 | S72 | Sugiyama | DCPS DCS1 HINT5 HSPC015 | VLRESARDKIIFLHGKVNEAsGDGDGEDAVVILEKTPFQVE |
| Q96D46 | T470 | Sugiyama | NMD3 CGI-07 | EAIRKNVNIyRDsAIPVEsDtDDEGAPRISLAEMLEDLHIs |
| Q96HE7 | S143 | Sugiyama | ERO1A ERO1L UNQ434/PRO865 | EANNLIEECEQAERLGAVDEsLsEEtQKAVLQWTKHDDSSD |
| Q96HE7 | S145 | Sugiyama | ERO1A ERO1L UNQ434/PRO865 | NNLIEECEQAERLGAVDEsLsEEtQKAVLQWTKHDDSSDNF |
| Q96HE7 | T148 | Sugiyama | ERO1A ERO1L UNQ434/PRO865 | IEECEQAERLGAVDEsLsEEtQKAVLQWTKHDDSSDNFCEA |
| Q96IR7 | S365 | Sugiyama | HPDL GLOXD1 | GATGFGQGNIRALWQsVQEQsARSQEA______________ |
| Q96QK1 | S760 | Sugiyama | VPS35 MEM3 TCCCTA00141 | IQVLNQLIQKIREDLPNLEssEEtEQINKHFHNtLEHLRLR |
| Q96QK1 | T763 | Sugiyama | VPS35 MEM3 TCCCTA00141 | LNQLIQKIREDLPNLEssEEtEQINKHFHNtLEHLRLRREs |
| Q99497 | S57 | Sugiyama | PARK7 | GLAGKDPVQCsRDVVICPDAsLEDAKKEGPyDVVVLPGGNL |
| Q99613 | S39 | Sugiyama | EIF3C EIF3S8 | GEELVTKPVGGNyGKQPLLLsEDEEDTKRVVRSAKDKRFEE |
| Q99613 | S865 | Sugiyama | EIF3C EIF3S8 | HRTEPTAQQNLALQLAEKLGsLVENNERVFDHKQGtyGGyF |
| Q99733 | S53 | Sugiyama | NAP1L4 NAP2 | QNPRVLAALQERLDNVPHtPssyIEtLPKAVKRRINALKQL |
| Q99733 | Y55 | Sugiyama | NAP1L4 NAP2 | PRVLAALQERLDNVPHtPssyIEtLPKAVKRRINALKQLQV |
| Q99832 | T351 | Sugiyama | CCT7 CCTH NIP7-1 | QtSVNALSADVLGRCQVFEEtQIGGERyNFFtGCPKAKTCt |
| Q9BQE3 | S439 | Sugiyama | TUBA1C TUBA6 | SEAREDMAALEKDyEEVGADsADGEDEGEEy__________ |
| Q9BQE3 | T73 | Sugiyama | TUBA1C TUBA6 | FsEtGAGKHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLI |
| Q9BQE3 | T80 | Sugiyama | TUBA1C TUBA6 | KHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAA |
| Q9BQE3 | Y449 | Sugiyama | TUBA1C TUBA6 | EKDyEEVGADsADGEDEGEEy____________________ |
| Q9BS26 | T154 | Sugiyama | ERP44 KIAA0573 TXNDC4 UNQ532/PRO1075 | DyIRQQKSDPIQEIRDLAEIttLDRSKRNIIGYFEQKDSDN |
| Q9BXJ9 | S855 | Sugiyama | NAA15 GA19 NARG1 NATH TBDN100 | ALAFMPPGYEEDMKItVNGDssAEAEELANEI_________ |
| Q9BYX7 | S239 | Sugiyama | POTEKP ACTBL3 FKSG30 | VALDSEQEMAMAASSSSVEKsyELPDGQVItIGNERFRCPE |
| Q9BYX7 | S368 | Sugiyama | POTEKP ACTBL3 FKSG30 | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| Q9BYX7 | Y240 | Sugiyama | POTEKP ACTBL3 FKSG30 | ALDSEQEMAMAASSSSVEKsyELPDGQVItIGNERFRCPEA |
| Q9BYX7 | Y362 | Sugiyama | POTEKP ACTBL3 FKSG30 | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCF_______ |
| Q9C0C2 | S1173 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | KttAGsVDWTDQLGLRNLEVssCVGsGGssEAREsAVGQMG |
| Q9C0C2 | T1323 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | ELGVGQMDWGNNLGLRDLEVtCDPDsGGsQGLRGCGVGQMD |
| Q9H6T3 | S503 | Sugiyama | RPAP3 | DDLFPTsDtPRAKVLKIEEVsDTssLQPQAsLKQDVCQsYs |
| Q9HCC0 | S256 | Sugiyama | MCCC2 MCCB | QGTIFLAGPPLVKAATGEEVsAEDLGGADLHCRKSGVSDHW |
| Q9HCN8 | S75 | Sugiyama | SDF2L1 UNQ1941/PRO4424 | SHDIKYGSGSGQQSVtGVEAsDDANSyWRIRGGSEGGCPRG |
| Q9NRX4 | T119 | Sugiyama | PHPT1 PHP14 CGI-202 HSPC141 | PAQHAISTEKIKAKyPDyEVtWANDGy______________ |
| Q9NWX6 | S298 | Sugiyama | THG1L ICF45 | HCDIIGDAFWKEHPEILDEDs____________________ |
| Q9NZ53 | S596 | Sugiyama | PODXL2 UNQ1861/PRO3742 | ALNGPGsWGALMGGKRDPEDsDVFEEDtHL___________ |
| Q9UHI6 | S677 | Sugiyama | DDX20 DP103 GEMIN3 | DSySSRTSSQSKGNKsyLEGssDNQLKDsEstPVDDRIsLE |
| Q9UI15 | S185 | Sugiyama | TAGLN3 NP25 | EQLRQGQNVIGLQMGSNKGAsQAGMtGyGMPRQIM______ |
| Q9UI15 | T190 | Sugiyama | TAGLN3 NP25 | GQNVIGLQMGSNKGAsQAGMtGyGMPRQIM___________ |
| Q9UI30 | T123 | Sugiyama | TRMT112 AD-001 HSPC152 HSPC170 | SGRMFPISRGIPNMLLsEEEtEs__________________ |
| Q9UNZ2 | S165 | Sugiyama | NSFL1C UBXN2C | SKPRPFAGGGYRLGAAPEEEsAyVAGEKRQHssQDVHVVLK |
| Q9UQ80 | T386 | Sugiyama | PA2G4 EBP1 | tQKKKKKKAsKtAENAtsGEtLEENEAGD____________ |
| Q9Y265 | S434 | Sugiyama | RUVBL1 INO80H NMP238 TIP49 TIP49A | NLLAKINGKDSIEKEHVEEIsELFyDAKSSAKILADQQDKY |
| Q9Y2B0 | S115 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | QIDPstHRKNYVRVVGRNGEssELDLQGIRIDsDISGtLKF |
| Q9Y2B0 | S116 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | IDPstHRKNYVRVVGRNGEssELDLQGIRIDsDISGtLKFA |
| Q9Y2B0 | S63 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | AQVDPKKTIQMGsFRINPDGsQsVVEVPyARsEAHLtELLE |
| Q9Y2B0 | S65 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | VDPKKTIQMGsFRINPDGsQsVVEVPyARsEAHLtELLEEI |
| Q9Y3B8 | S201 | Sugiyama | REXO2 SFN SMFN CGI-114 | PEEYEFAPKKAAsHRALDDIsEsIKELQFyRNNIFKKKIDE |
| Q9Y3B8 | S203 | Sugiyama | REXO2 SFN SMFN CGI-114 | EYEFAPKKAAsHRALDDIsEsIKELQFyRNNIFKKKIDEKK |
| Q9Y3F4 | S312 | Sugiyama | STRAP MAWD UNRIP | WQTVVGKtyGLWKCVLPEEDsGELAKPKIGFPETTEEELEE |
| Q9Y3U8 | S91 | Sugiyama | RPL36 | KFIKKRVGTHIRAKRKREELsNVLAAMRKAAAKKD______ |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Chromatin modifying enzymes | R-HSA-3247509 | 0.000001 | 5.945 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 0.000001 | 5.829 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 0.000003 | 5.600 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 0.000004 | 5.425 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 0.000005 | 5.295 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 0.000031 | 4.515 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 0.000062 | 4.208 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 0.000074 | 4.133 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 0.000100 | 3.998 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 0.000171 | 3.766 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 0.000223 | 3.653 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 0.000376 | 3.425 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 0.000390 | 3.409 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 0.000456 | 3.341 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 0.000558 | 3.253 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 0.000563 | 3.249 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 0.000626 | 3.203 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 0.000914 | 3.039 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 0.000990 | 3.004 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 0.001207 | 2.918 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 0.001291 | 2.889 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 0.001405 | 2.852 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 0.001438 | 2.842 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 0.001509 | 2.821 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 0.001550 | 2.810 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 0.001590 | 2.798 | 0 | 0 |
| M Phase | R-HSA-68886 | 0.001699 | 2.770 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 0.001698 | 2.770 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 0.002076 | 2.683 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 0.002160 | 2.666 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 0.002217 | 2.654 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 0.002340 | 2.631 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 0.002521 | 2.598 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 0.002521 | 2.598 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 0.002889 | 2.539 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 0.003351 | 2.475 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 0.003806 | 2.419 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 0.003711 | 2.431 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 0.004012 | 2.397 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 0.003940 | 2.405 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 0.005108 | 2.292 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 0.005108 | 2.292 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 0.004994 | 2.302 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 0.005110 | 2.292 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 0.004672 | 2.331 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 0.004994 | 2.302 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 0.005095 | 2.293 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 0.005194 | 2.284 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 0.005706 | 2.244 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 0.006230 | 2.205 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 0.006490 | 2.188 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 0.007353 | 2.134 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 0.007409 | 2.130 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 0.007800 | 2.108 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 0.007696 | 2.114 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 0.008197 | 2.086 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 0.008187 | 2.087 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 0.008297 | 2.081 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 0.008950 | 2.048 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 0.008950 | 2.048 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 0.008488 | 2.071 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 0.009252 | 2.034 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 0.008723 | 2.059 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 0.010552 | 1.977 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 0.010881 | 1.963 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 0.010881 | 1.963 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 0.010881 | 1.963 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 0.010881 | 1.963 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 0.010450 | 1.981 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 0.009680 | 2.014 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 0.010355 | 1.985 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 0.010710 | 1.970 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 0.011552 | 1.937 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 0.012070 | 1.918 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 0.012070 | 1.918 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 0.012646 | 1.898 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 0.012944 | 1.888 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 0.012981 | 1.887 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 0.014280 | 1.845 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 0.014280 | 1.845 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 0.015062 | 1.822 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 0.014783 | 1.830 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 0.014400 | 1.842 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 0.015409 | 1.812 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 0.015590 | 1.807 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 0.015816 | 1.801 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 0.016055 | 1.794 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 0.016195 | 1.791 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 0.016278 | 1.788 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 0.017584 | 1.755 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 0.017564 | 1.755 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 0.017977 | 1.745 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 0.018591 | 1.731 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 0.018591 | 1.731 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 0.020605 | 1.686 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 0.020759 | 1.683 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 0.020752 | 1.683 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 0.020052 | 1.698 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 0.021156 | 1.675 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 0.021973 | 1.658 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 0.022035 | 1.657 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 0.022283 | 1.652 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 0.023181 | 1.635 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 0.024195 | 1.616 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 0.024675 | 1.608 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 0.024675 | 1.608 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 0.023643 | 1.626 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 0.024834 | 1.605 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 0.024834 | 1.605 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 0.025300 | 1.597 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 0.025939 | 1.586 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 0.025939 | 1.586 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 0.028804 | 1.541 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 0.026746 | 1.573 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 0.026746 | 1.573 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 0.026921 | 1.570 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 0.026746 | 1.573 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 0.027166 | 1.566 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 0.028804 | 1.541 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 0.026844 | 1.571 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 0.029630 | 1.528 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 0.029961 | 1.523 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 0.030448 | 1.516 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 0.030998 | 1.509 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 0.030998 | 1.509 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 0.031246 | 1.505 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 0.031246 | 1.505 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 0.034807 | 1.458 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 0.034807 | 1.458 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 0.033288 | 1.478 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 0.034771 | 1.459 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 0.031756 | 1.498 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 0.035939 | 1.444 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 0.036549 | 1.437 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 0.038196 | 1.418 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 0.038207 | 1.418 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 0.038358 | 1.416 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 0.038747 | 1.412 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 0.038747 | 1.412 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 0.039195 | 1.407 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 0.040092 | 1.397 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 0.040092 | 1.397 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 0.047119 | 1.327 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 0.046462 | 1.333 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 0.045997 | 1.337 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 0.043592 | 1.361 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 0.042632 | 1.370 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 0.046253 | 1.335 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 0.049295 | 1.307 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 0.050489 | 1.297 | 0 | 0 |
| Deletions in the AMER1 gene destabilize the destruction complex | R-HSA-5467343 | 0.051005 | 1.292 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 0.052181 | 1.282 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 0.052181 | 1.282 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 0.052553 | 1.279 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 0.052755 | 1.278 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 0.052755 | 1.278 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 0.055103 | 1.259 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 0.055103 | 1.259 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 0.054008 | 1.268 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 0.061263 | 1.213 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 0.061300 | 1.213 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 0.056268 | 1.250 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 0.054008 | 1.268 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 0.055103 | 1.259 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 0.059164 | 1.228 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 0.060694 | 1.217 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 0.055103 | 1.259 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 0.055794 | 1.253 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 0.061494 | 1.211 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 0.099412 | 1.003 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 0.099412 | 1.003 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 0.099412 | 1.003 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 0.099412 | 1.003 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 0.099412 | 1.003 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 0.099412 | 1.003 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 0.145352 | 0.838 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 0.145352 | 0.838 | 0 | 0 |
| Defective SLC17A5 causes Salla disease (SD) and ISSD | R-HSA-5619035 | 0.145352 | 0.838 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 0.145352 | 0.838 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 0.145352 | 0.838 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 0.188952 | 0.724 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 0.188952 | 0.724 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 0.188952 | 0.724 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 0.188952 | 0.724 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 0.188952 | 0.724 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 0.188952 | 0.724 | 0 | 0 |
| Defective ABCB6 causes MCOPCB7 | R-HSA-5683371 | 0.188952 | 0.724 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 0.188952 | 0.724 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 0.188952 | 0.724 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 0.188952 | 0.724 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 0.188952 | 0.724 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 0.188952 | 0.724 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 0.188952 | 0.724 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 0.188952 | 0.724 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 0.097368 | 1.012 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 0.097368 | 1.012 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 0.097368 | 1.012 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 0.230330 | 0.638 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 0.230330 | 0.638 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 0.230330 | 0.638 | 0 | 0 |
| Adrenaline signalling through Alpha-2 adrenergic receptor | R-HSA-392023 | 0.230330 | 0.638 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 0.230330 | 0.638 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 0.113970 | 0.943 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 0.113970 | 0.943 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 0.131227 | 0.882 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 0.269599 | 0.569 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 0.269599 | 0.569 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 0.269599 | 0.569 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 0.149031 | 0.827 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 0.089034 | 1.050 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 0.306867 | 0.513 | 0 | 0 |
| IRS activation | R-HSA-74713 | 0.306867 | 0.513 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 0.306867 | 0.513 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 0.306867 | 0.513 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 0.074623 | 1.127 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 0.074623 | 1.127 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 0.185883 | 0.731 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 0.185883 | 0.731 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 0.185883 | 0.731 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 0.185883 | 0.731 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 0.204756 | 0.689 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 0.204756 | 0.689 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 0.204756 | 0.689 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 0.204756 | 0.689 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 0.204756 | 0.689 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 0.342235 | 0.466 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 0.342235 | 0.466 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 0.342235 | 0.466 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 0.342235 | 0.466 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 0.342235 | 0.466 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 0.097157 | 1.013 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 0.144786 | 0.839 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 0.144786 | 0.839 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 0.105299 | 0.978 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 0.105299 | 0.978 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 0.105299 | 0.978 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 0.113740 | 0.944 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 0.122468 | 0.912 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 0.169645 | 0.770 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 0.375801 | 0.425 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 0.375801 | 0.425 | 0 | 0 |
| Defective CHST14 causes EDS, musculocontractural type | R-HSA-3595174 | 0.375801 | 0.425 | 0 | 0 |
| Defective CHST3 causes SEDCJD | R-HSA-3595172 | 0.375801 | 0.425 | 0 | 0 |
| Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) | R-HSA-5619070 | 0.375801 | 0.425 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 0.375801 | 0.425 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 0.071903 | 1.143 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 0.182506 | 0.739 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 0.103311 | 0.986 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 0.262275 | 0.581 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 0.262275 | 0.581 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 0.262275 | 0.581 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 0.262275 | 0.581 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 0.262275 | 0.581 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 0.195617 | 0.709 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 0.195617 | 0.709 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 0.098416 | 1.007 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 0.160016 | 0.796 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 0.208948 | 0.680 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 0.281540 | 0.550 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 0.407656 | 0.390 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 0.407656 | 0.390 | 0 | 0 |
| Defective CHSY1 causes TPBS | R-HSA-3595177 | 0.407656 | 0.390 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 0.407656 | 0.390 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 0.407656 | 0.390 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 0.104265 | 0.982 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 0.104265 | 0.982 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 0.300760 | 0.522 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 0.300760 | 0.522 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 0.300760 | 0.522 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 0.300760 | 0.522 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 0.190581 | 0.720 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 0.156231 | 0.806 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 0.249997 | 0.602 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 0.319892 | 0.495 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 0.437887 | 0.359 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 0.437887 | 0.359 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 0.437887 | 0.359 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 0.437887 | 0.359 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 0.437887 | 0.359 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 0.263945 | 0.578 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 0.338893 | 0.470 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 0.338893 | 0.470 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 0.136677 | 0.864 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 0.277985 | 0.556 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 0.149110 | 0.826 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 0.149110 | 0.826 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 0.357727 | 0.446 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 0.357727 | 0.446 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 0.123233 | 0.909 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 0.376363 | 0.424 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 0.376363 | 0.424 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 0.149496 | 0.825 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 0.394771 | 0.404 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 0.265901 | 0.575 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 0.182487 | 0.739 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 0.313994 | 0.503 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 0.313994 | 0.503 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 0.313994 | 0.503 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 0.285721 | 0.544 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 0.362924 | 0.440 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 0.325697 | 0.487 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 0.248894 | 0.604 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 0.430805 | 0.366 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 0.430805 | 0.366 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 0.430805 | 0.366 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 0.315921 | 0.500 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 0.315921 | 0.500 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 0.297207 | 0.527 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 0.346494 | 0.460 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 0.384389 | 0.415 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 0.384389 | 0.415 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 0.396088 | 0.402 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 0.396088 | 0.402 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 0.377231 | 0.423 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 0.290524 | 0.537 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 0.419367 | 0.377 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 0.430929 | 0.366 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 0.366979 | 0.435 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 0.306249 | 0.514 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 0.092031 | 1.036 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 0.103311 | 0.986 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 0.334614 | 0.475 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 0.223824 | 0.650 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 0.362924 | 0.440 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 0.277985 | 0.556 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 0.149496 | 0.825 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 0.199562 | 0.700 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 0.210994 | 0.676 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 0.275347 | 0.560 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 0.080046 | 1.097 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 0.349172 | 0.457 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 0.190581 | 0.720 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 0.103311 | 0.986 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 0.150259 | 0.823 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 0.169645 | 0.770 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 0.117394 | 0.930 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 0.156231 | 0.806 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 0.156231 | 0.806 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 0.292094 | 0.534 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 0.223824 | 0.650 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 0.123365 | 0.909 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 0.150259 | 0.823 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 0.397717 | 0.400 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 0.397717 | 0.400 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 0.430805 | 0.366 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 0.148075 | 0.830 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 0.069899 | 1.156 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 0.149031 | 0.827 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 0.081810 | 1.087 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 0.081810 | 1.087 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 0.096603 | 1.015 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 0.262275 | 0.581 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 0.281540 | 0.550 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 0.320429 | 0.494 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 0.169997 | 0.770 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 0.201155 | 0.696 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 0.387479 | 0.412 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 0.066580 | 1.177 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 0.156231 | 0.806 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 0.122468 | 0.912 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 0.290714 | 0.537 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 0.412926 | 0.384 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 0.261831 | 0.582 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 0.380096 | 0.420 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 0.182370 | 0.739 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 0.132332 | 0.878 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 0.269599 | 0.569 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 0.079213 | 1.101 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 0.169645 | 0.770 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 0.131472 | 0.881 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 0.300760 | 0.522 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 0.338893 | 0.470 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 0.357727 | 0.446 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 0.182370 | 0.739 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 0.277985 | 0.556 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 0.292094 | 0.534 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 0.377013 | 0.424 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 0.227671 | 0.643 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 0.202544 | 0.693 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 0.357727 | 0.446 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 0.148075 | 0.830 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 0.081810 | 1.087 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 0.249997 | 0.602 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 0.236077 | 0.627 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 0.377013 | 0.424 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 0.325697 | 0.487 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 0.418135 | 0.379 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 0.281540 | 0.550 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 0.139884 | 0.854 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 0.069899 | 1.156 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 0.306867 | 0.513 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 0.121271 | 0.916 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 0.204756 | 0.689 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 0.150259 | 0.823 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 0.407656 | 0.390 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 0.222472 | 0.653 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 0.300760 | 0.522 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 0.211899 | 0.674 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 0.277985 | 0.556 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 0.267686 | 0.572 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 0.376363 | 0.424 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 0.376363 | 0.424 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 0.394771 | 0.404 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 0.217203 | 0.663 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 0.404978 | 0.393 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 0.346463 | 0.460 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 0.246410 | 0.608 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 0.121271 | 0.916 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 0.244576 | 0.612 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 0.372664 | 0.429 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 0.202544 | 0.693 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 0.297207 | 0.527 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 0.193226 | 0.714 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 0.236164 | 0.627 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 0.149496 | 0.825 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 0.097368 | 1.012 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 0.167280 | 0.777 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 0.182506 | 0.739 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 0.062650 | 1.203 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 0.236164 | 0.627 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 0.412926 | 0.384 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 0.430805 | 0.366 | 0 | 0 |
| S Phase | R-HSA-69242 | 0.257195 | 0.590 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 0.292094 | 0.534 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 0.277985 | 0.556 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 0.292094 | 0.534 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 0.329769 | 0.482 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 0.236164 | 0.627 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 0.305803 | 0.515 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 0.404978 | 0.393 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 0.397717 | 0.400 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 0.320429 | 0.494 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 0.113746 | 0.944 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 0.376363 | 0.424 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 0.117394 | 0.930 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 0.095075 | 1.022 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 0.203073 | 0.692 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 0.203570 | 0.691 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 0.121271 | 0.916 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 0.066261 | 1.179 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 0.279208 | 0.554 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 0.265488 | 0.576 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 0.142828 | 0.845 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 0.145352 | 0.838 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 0.230330 | 0.638 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 0.131227 | 0.882 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 0.269599 | 0.569 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 0.306867 | 0.513 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 0.185883 | 0.731 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 0.342235 | 0.466 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 0.066580 | 1.177 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 0.223824 | 0.650 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 0.223824 | 0.650 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 0.375801 | 0.425 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 0.262275 | 0.581 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 0.407656 | 0.390 | 0 | 0 |
| Mitochondrial ABC transporters | R-HSA-1369007 | 0.407656 | 0.390 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 0.156231 | 0.806 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 0.319892 | 0.495 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 0.437887 | 0.359 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 0.233841 | 0.631 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 0.233841 | 0.631 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 0.171923 | 0.765 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 0.357727 | 0.446 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 0.348785 | 0.457 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 0.275774 | 0.559 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 0.265488 | 0.576 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 0.384389 | 0.415 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 0.286142 | 0.543 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 0.157638 | 0.802 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 0.286142 | 0.543 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 0.287796 | 0.541 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 0.249997 | 0.602 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 0.208683 | 0.681 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 0.222940 | 0.652 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 0.245012 | 0.611 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 0.156231 | 0.806 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 0.101025 | 0.996 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 0.371633 | 0.430 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 0.325697 | 0.487 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 0.310421 | 0.508 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 0.131227 | 0.882 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 0.204756 | 0.689 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 0.372143 | 0.429 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 0.137067 | 0.863 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 0.310421 | 0.508 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 0.272953 | 0.564 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 0.069899 | 1.156 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 0.348785 | 0.457 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 0.157874 | 0.802 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 0.218399 | 0.661 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 0.262388 | 0.581 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 0.183760 | 0.736 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 0.427025 | 0.370 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 0.229874 | 0.639 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 0.079213 | 1.101 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 0.089034 | 1.050 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 0.306867 | 0.513 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 0.204756 | 0.689 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 0.090124 | 1.045 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 0.140740 | 0.852 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 0.150259 | 0.823 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 0.407656 | 0.390 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 0.222472 | 0.653 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 0.249997 | 0.602 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 0.320429 | 0.494 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 0.295293 | 0.530 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 0.219200 | 0.659 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 0.246410 | 0.608 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 0.104678 | 0.980 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 0.190582 | 0.720 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 0.317106 | 0.499 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 0.089034 | 1.050 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 0.243018 | 0.614 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 0.217937 | 0.662 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 0.306249 | 0.514 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 0.380038 | 0.420 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 0.285721 | 0.544 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 0.194441 | 0.711 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 0.394771 | 0.404 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 0.366979 | 0.435 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 0.334614 | 0.475 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 0.084586 | 1.073 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 0.136677 | 0.864 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 0.182370 | 0.739 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 0.157062 | 0.804 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 0.157062 | 0.804 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 0.062602 | 1.203 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 0.397717 | 0.400 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 0.430805 | 0.366 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 0.216085 | 0.665 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 0.097157 | 1.013 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 0.216085 | 0.665 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 0.216085 | 0.665 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 0.113970 | 0.943 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 0.269599 | 0.569 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 0.269599 | 0.569 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 0.110092 | 0.958 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 0.110092 | 0.958 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 0.342235 | 0.466 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 0.375801 | 0.425 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 0.150259 | 0.823 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 0.407656 | 0.390 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 0.407656 | 0.390 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 0.236164 | 0.627 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 0.319892 | 0.495 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 0.437887 | 0.359 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 0.437887 | 0.359 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 0.338893 | 0.470 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 0.245012 | 0.611 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 0.357727 | 0.446 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 0.396970 | 0.401 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 0.072985 | 1.137 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 0.096287 | 1.016 | 1 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 0.067633 | 1.170 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 0.302836 | 0.519 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 0.169645 | 0.770 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 0.277985 | 0.556 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 0.092005 | 1.036 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 0.071558 | 1.145 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 0.143435 | 0.843 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 0.144786 | 0.839 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 0.069191 | 1.160 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 0.148242 | 0.829 | 1 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 0.166928 | 0.777 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 0.077521 | 1.111 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 0.157062 | 0.804 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 0.096603 | 1.015 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 0.319892 | 0.495 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 0.338102 | 0.471 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 0.338893 | 0.470 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 0.326081 | 0.487 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 0.333397 | 0.477 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 0.356633 | 0.448 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 0.081543 | 1.089 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 0.131227 | 0.882 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 0.132846 | 0.877 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 0.157062 | 0.804 | 0 | 0 |
| Kinesins | R-HSA-983189 | 0.069585 | 1.157 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 0.150259 | 0.823 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 0.180190 | 0.744 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 0.285721 | 0.544 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 0.207209 | 0.684 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 0.308419 | 0.511 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 0.121271 | 0.916 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 0.338893 | 0.470 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 0.302329 | 0.520 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 0.302329 | 0.520 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 0.270576 | 0.568 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 0.190581 | 0.720 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 0.282852 | 0.548 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 0.124759 | 0.904 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 0.337427 | 0.472 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 0.362651 | 0.441 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 0.185107 | 0.733 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 0.269599 | 0.569 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 0.167280 | 0.777 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 0.306867 | 0.513 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 0.342235 | 0.466 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 0.169645 | 0.770 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 0.375801 | 0.425 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 0.375801 | 0.425 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 0.375801 | 0.425 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 0.407656 | 0.390 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 0.407656 | 0.390 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 0.407656 | 0.390 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 0.437887 | 0.359 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 0.338893 | 0.470 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 0.428303 | 0.368 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 0.315921 | 0.500 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 0.300145 | 0.523 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 0.067626 | 1.170 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 0.157062 | 0.804 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 0.306249 | 0.514 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 0.275774 | 0.559 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 0.150259 | 0.823 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 0.356731 | 0.448 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 0.225708 | 0.646 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 0.387479 | 0.412 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 0.222234 | 0.653 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 0.222360 | 0.653 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 0.156231 | 0.806 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 0.097368 | 1.012 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 0.131227 | 0.882 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 0.079213 | 1.101 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 0.306867 | 0.513 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 0.342235 | 0.466 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 0.342235 | 0.466 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 0.375801 | 0.425 | 0 | 0 |
| Lipid particle organization | R-HSA-8964572 | 0.375801 | 0.425 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 0.182506 | 0.739 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 0.407656 | 0.390 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 0.182370 | 0.739 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 0.315921 | 0.500 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 0.176485 | 0.753 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 0.222799 | 0.652 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 0.209311 | 0.679 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 0.407938 | 0.389 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 0.342572 | 0.465 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 0.087887 | 1.056 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 0.325705 | 0.487 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 0.342235 | 0.466 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 0.236164 | 0.627 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 0.437887 | 0.359 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 0.087887 | 1.056 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 0.419367 | 0.377 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 0.279162 | 0.554 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 0.394771 | 0.404 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 0.201926 | 0.695 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 0.176636 | 0.753 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 0.206980 | 0.684 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 0.227957 | 0.642 | 1 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 0.079213 | 1.101 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 0.375801 | 0.425 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 0.169997 | 0.770 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 0.164466 | 0.784 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 0.357727 | 0.446 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 0.334614 | 0.475 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 0.326195 | 0.487 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 0.290714 | 0.537 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 0.313994 | 0.503 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 0.306867 | 0.513 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 0.391036 | 0.408 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 0.222799 | 0.652 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 0.226633 | 0.645 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 0.338893 | 0.470 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 0.337427 | 0.472 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 0.222472 | 0.653 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 0.122468 | 0.912 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 0.384389 | 0.415 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 0.302329 | 0.520 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 0.319892 | 0.495 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 0.292094 | 0.534 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 0.280349 | 0.552 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 0.190581 | 0.720 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 0.384389 | 0.415 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 0.089868 | 1.046 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 0.418826 | 0.378 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 0.324313 | 0.489 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 0.357727 | 0.446 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 0.391036 | 0.408 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 0.222799 | 0.652 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 0.113740 | 0.944 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 0.187244 | 0.728 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 0.391036 | 0.408 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 0.204756 | 0.689 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 0.275774 | 0.559 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 0.262275 | 0.581 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 0.169997 | 0.770 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 0.279390 | 0.554 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 0.388552 | 0.411 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 0.439073 | 0.357 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 0.439860 | 0.357 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 0.446182 | 0.350 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 0.446182 | 0.350 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 0.446182 | 0.350 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 0.447791 | 0.349 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 0.448255 | 0.348 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 0.448391 | 0.348 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 0.448391 | 0.348 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 0.451391 | 0.345 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 0.452720 | 0.344 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 0.453858 | 0.343 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 0.458981 | 0.338 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 0.459668 | 0.338 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 0.465209 | 0.332 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 0.465666 | 0.332 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 0.465666 | 0.332 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 0.465666 | 0.332 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 0.465666 | 0.332 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 0.465666 | 0.332 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 0.465666 | 0.332 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 0.466577 | 0.331 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 0.466577 | 0.331 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 0.466577 | 0.331 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 0.466577 | 0.331 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 0.466577 | 0.331 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 0.466577 | 0.331 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 0.466577 | 0.331 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 0.466577 | 0.331 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 0.466577 | 0.331 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 0.466577 | 0.331 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 0.466577 | 0.331 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 0.466577 | 0.331 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 0.466577 | 0.331 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 0.466577 | 0.331 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 0.466577 | 0.331 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 0.466577 | 0.331 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 0.466577 | 0.331 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 0.468558 | 0.329 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 0.473011 | 0.325 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 0.476475 | 0.322 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 0.476475 | 0.322 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 0.476475 | 0.322 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 0.476475 | 0.322 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 0.476475 | 0.322 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 0.476475 | 0.322 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 0.476475 | 0.322 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 0.482616 | 0.316 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 0.482616 | 0.316 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 0.482616 | 0.316 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 0.484380 | 0.315 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 0.486201 | 0.313 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 0.487649 | 0.312 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 0.488255 | 0.311 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 0.488734 | 0.311 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 0.488937 | 0.311 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 0.493165 | 0.307 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 0.493745 | 0.306 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 0.493804 | 0.306 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 0.493804 | 0.306 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 0.493804 | 0.306 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 0.493804 | 0.306 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 0.493804 | 0.306 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 0.493804 | 0.306 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 0.493804 | 0.306 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 0.493804 | 0.306 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 0.493804 | 0.306 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 0.493804 | 0.306 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 0.493804 | 0.306 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 0.493804 | 0.306 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 0.495049 | 0.305 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 0.496212 | 0.304 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 0.497623 | 0.303 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 0.498724 | 0.302 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 0.498724 | 0.302 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 0.498724 | 0.302 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 0.499229 | 0.302 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 0.499229 | 0.302 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 0.499229 | 0.302 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 0.499229 | 0.302 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 0.499230 | 0.302 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 0.499230 | 0.302 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 0.502582 | 0.299 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 0.504254 | 0.297 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 0.505269 | 0.296 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 0.509695 | 0.293 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 0.509695 | 0.293 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 0.509695 | 0.293 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 0.511823 | 0.291 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 0.512089 | 0.291 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 0.512089 | 0.291 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 0.515496 | 0.288 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 0.515496 | 0.288 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 0.515496 | 0.288 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 0.515496 | 0.288 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 0.519643 | 0.284 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 0.519643 | 0.284 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 0.519643 | 0.284 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 0.519643 | 0.284 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 0.519643 | 0.284 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 0.519643 | 0.284 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 0.519643 | 0.284 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 0.519643 | 0.284 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 0.519643 | 0.284 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 0.519643 | 0.284 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 0.519643 | 0.284 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 0.524771 | 0.280 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 0.524771 | 0.280 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 0.524771 | 0.280 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 0.524771 | 0.280 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 0.527119 | 0.278 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 0.531408 | 0.275 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 0.531408 | 0.275 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 0.532608 | 0.274 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 0.533818 | 0.273 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 0.534043 | 0.272 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 0.536608 | 0.270 | 0 | 0 |
| DS-GAG biosynthesis | R-HSA-2022923 | 0.544165 | 0.264 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 0.544165 | 0.264 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 0.544165 | 0.264 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 0.544165 | 0.264 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 0.544165 | 0.264 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 0.544165 | 0.264 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 0.544165 | 0.264 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 0.544165 | 0.264 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 0.544165 | 0.264 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 0.544165 | 0.264 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 0.546008 | 0.263 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 0.546008 | 0.263 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 0.546960 | 0.262 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 0.546960 | 0.262 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 0.549054 | 0.260 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 0.551765 | 0.258 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 0.552428 | 0.258 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 0.552533 | 0.258 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 0.558162 | 0.253 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 0.560934 | 0.251 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 0.562147 | 0.250 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 0.562291 | 0.250 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 0.564531 | 0.248 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 0.566534 | 0.247 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 0.566534 | 0.247 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 0.566940 | 0.246 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 0.567436 | 0.246 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 0.567436 | 0.246 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 0.567436 | 0.246 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 0.567436 | 0.246 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 0.567436 | 0.246 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 0.567436 | 0.246 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 0.567436 | 0.246 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 0.567436 | 0.246 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 0.567436 | 0.246 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 0.567436 | 0.246 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 0.567436 | 0.246 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 0.567436 | 0.246 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 0.567436 | 0.246 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 0.567436 | 0.246 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 0.567436 | 0.246 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 0.567436 | 0.246 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 0.567436 | 0.246 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 0.567436 | 0.246 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 0.567436 | 0.246 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 0.573604 | 0.241 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 0.573604 | 0.241 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 0.573604 | 0.241 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 0.573647 | 0.241 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 0.575100 | 0.240 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 0.576965 | 0.239 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 0.576965 | 0.239 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 0.576965 | 0.239 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 0.576965 | 0.239 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 0.576965 | 0.239 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 0.583143 | 0.234 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 0.585313 | 0.233 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 0.587073 | 0.231 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 0.587887 | 0.231 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 0.589520 | 0.230 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 0.589520 | 0.230 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 0.589520 | 0.230 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 0.589520 | 0.230 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 0.589520 | 0.230 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 0.589520 | 0.230 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 0.589520 | 0.230 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 0.589520 | 0.230 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 0.589520 | 0.230 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 0.591006 | 0.228 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 0.591413 | 0.228 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 0.591574 | 0.228 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 0.594179 | 0.226 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 0.598905 | 0.223 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 0.598905 | 0.223 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 0.598905 | 0.223 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 0.605490 | 0.218 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 0.605490 | 0.218 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 0.606023 | 0.218 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 0.607195 | 0.217 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 0.610252 | 0.214 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 0.610478 | 0.214 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 0.610478 | 0.214 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 0.610478 | 0.214 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 0.610478 | 0.214 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 0.610478 | 0.214 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 0.610478 | 0.214 | 0 | 0 |
| Protein folding | R-HSA-391251 | 0.617665 | 0.209 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 0.619187 | 0.208 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 0.619196 | 0.208 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 0.619196 | 0.208 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 0.625783 | 0.204 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 0.630051 | 0.201 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 0.630051 | 0.201 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 0.630368 | 0.200 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 0.630368 | 0.200 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 0.630368 | 0.200 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 0.630368 | 0.200 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 0.630368 | 0.200 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 0.630368 | 0.200 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 0.630368 | 0.200 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 0.630368 | 0.200 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 0.630368 | 0.200 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 0.630368 | 0.200 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 0.630368 | 0.200 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 0.630368 | 0.200 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 0.630368 | 0.200 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 0.630368 | 0.200 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 0.632532 | 0.199 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 0.632532 | 0.199 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 0.632532 | 0.199 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 0.632532 | 0.199 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 0.632532 | 0.199 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 0.640744 | 0.193 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 0.640744 | 0.193 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 0.640744 | 0.193 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 0.645500 | 0.190 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 0.646225 | 0.190 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 0.649243 | 0.188 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 0.649243 | 0.188 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 0.649243 | 0.188 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 0.649243 | 0.188 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 0.649243 | 0.188 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 0.649243 | 0.188 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 0.649243 | 0.188 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 0.649243 | 0.188 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 0.649243 | 0.188 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 0.649243 | 0.188 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 0.649243 | 0.188 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 0.649243 | 0.188 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 0.651130 | 0.186 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 0.651130 | 0.186 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 0.651130 | 0.186 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 0.651130 | 0.186 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 0.651130 | 0.186 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 0.654595 | 0.184 | 0 | 0 |
| Translation | R-HSA-72766 | 0.656424 | 0.183 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 0.658103 | 0.182 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 0.658103 | 0.182 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 0.658103 | 0.182 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 0.658103 | 0.182 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 0.658103 | 0.182 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 0.658744 | 0.181 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 0.658744 | 0.181 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 0.660218 | 0.180 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 0.661343 | 0.180 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 0.661343 | 0.180 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 0.661473 | 0.179 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 0.662695 | 0.179 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 0.665420 | 0.177 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 0.667155 | 0.176 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 0.667155 | 0.176 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 0.667155 | 0.176 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 0.667155 | 0.176 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 0.667155 | 0.176 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 0.667155 | 0.176 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 0.667155 | 0.176 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 0.667155 | 0.176 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 0.667512 | 0.176 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 0.669412 | 0.174 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 0.670344 | 0.174 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 0.670344 | 0.174 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 0.670344 | 0.174 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 0.670344 | 0.174 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 0.670344 | 0.174 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 0.670344 | 0.174 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 0.671678 | 0.173 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 0.674298 | 0.171 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 0.674298 | 0.171 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 0.676125 | 0.170 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 0.679681 | 0.168 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 0.682229 | 0.166 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 0.684153 | 0.165 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 0.684153 | 0.165 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 0.684153 | 0.165 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 0.684153 | 0.165 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 0.684153 | 0.165 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 0.684153 | 0.165 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 0.688115 | 0.162 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 0.688969 | 0.162 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 0.692356 | 0.160 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 0.693760 | 0.159 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 0.693760 | 0.159 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 0.697133 | 0.157 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 0.700014 | 0.155 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 0.700014 | 0.155 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 0.700014 | 0.155 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 0.700285 | 0.155 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 0.700285 | 0.155 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 0.700285 | 0.155 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 0.700285 | 0.155 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 0.700285 | 0.155 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 0.700285 | 0.155 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 0.700285 | 0.155 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 0.700285 | 0.155 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 0.700285 | 0.155 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 0.700285 | 0.155 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 0.704417 | 0.152 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 0.704943 | 0.152 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 0.704943 | 0.152 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 0.704943 | 0.152 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 0.704943 | 0.152 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 0.704943 | 0.152 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 0.704943 | 0.152 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 0.704943 | 0.152 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 0.704943 | 0.152 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 0.707791 | 0.150 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 0.709140 | 0.149 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 0.709140 | 0.149 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 0.709140 | 0.149 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 0.715593 | 0.145 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 0.715593 | 0.145 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 0.715593 | 0.145 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 0.715593 | 0.145 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 0.715593 | 0.145 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 0.715593 | 0.145 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 0.715593 | 0.145 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 0.715593 | 0.145 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 0.715593 | 0.145 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 0.715593 | 0.145 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 0.715778 | 0.145 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 0.715784 | 0.145 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 0.715784 | 0.145 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 0.715784 | 0.145 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 0.715784 | 0.145 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 0.716841 | 0.145 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 0.721846 | 0.142 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 0.724749 | 0.140 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 0.726288 | 0.139 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 0.726288 | 0.139 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 0.726288 | 0.139 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 0.726288 | 0.139 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 0.726288 | 0.139 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 0.726288 | 0.139 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 0.726616 | 0.139 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 0.726748 | 0.139 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 0.726748 | 0.139 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 0.730120 | 0.137 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 0.730120 | 0.137 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 0.730120 | 0.137 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 0.730120 | 0.137 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 0.730120 | 0.137 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 0.730120 | 0.137 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 0.730120 | 0.137 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 0.730120 | 0.137 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 0.735233 | 0.134 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 0.743907 | 0.128 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 0.743907 | 0.128 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 0.743907 | 0.128 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 0.743907 | 0.128 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 0.743907 | 0.128 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 0.743907 | 0.128 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 0.746311 | 0.127 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 0.746311 | 0.127 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 0.746311 | 0.127 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 0.750168 | 0.125 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 0.751579 | 0.124 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 0.752444 | 0.124 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 0.753325 | 0.123 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 0.753662 | 0.123 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 0.755843 | 0.122 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 0.755843 | 0.122 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 0.755843 | 0.122 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 0.755843 | 0.122 | 0 | 0 |
| CS-GAG biosynthesis | R-HSA-2022870 | 0.756989 | 0.121 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 0.756989 | 0.121 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 0.756989 | 0.121 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 0.756989 | 0.121 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 0.756989 | 0.121 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 0.756989 | 0.121 | 0 | 0 |
| Immune System | R-HSA-168256 | 0.757013 | 0.121 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 0.759443 | 0.120 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 0.759443 | 0.120 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 0.760566 | 0.119 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 0.765063 | 0.116 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 0.765063 | 0.116 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 0.765063 | 0.116 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 0.765063 | 0.116 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 0.765063 | 0.116 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 0.767318 | 0.115 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 0.769404 | 0.114 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 0.769404 | 0.114 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 0.769404 | 0.114 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 0.769404 | 0.114 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 0.769404 | 0.114 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 0.769404 | 0.114 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 0.771994 | 0.112 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 0.772353 | 0.112 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 0.773980 | 0.111 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 0.774565 | 0.111 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 0.774565 | 0.111 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 0.775104 | 0.111 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 0.776530 | 0.110 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 0.780376 | 0.108 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 0.781186 | 0.107 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 0.781186 | 0.107 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 0.781186 | 0.107 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 0.781186 | 0.107 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 0.781186 | 0.107 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 0.781186 | 0.107 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 0.781186 | 0.107 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 0.782600 | 0.106 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 0.782600 | 0.106 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 0.784946 | 0.105 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 0.786683 | 0.104 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 0.787399 | 0.104 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 0.788900 | 0.103 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 0.790930 | 0.102 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 0.790930 | 0.102 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 0.791857 | 0.101 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 0.792366 | 0.101 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 0.792366 | 0.101 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 0.792366 | 0.101 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 0.792366 | 0.101 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 0.792846 | 0.101 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 0.795779 | 0.099 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 0.798977 | 0.097 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 0.798977 | 0.097 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 0.798977 | 0.097 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 0.802469 | 0.096 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 0.802976 | 0.095 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 0.802976 | 0.095 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 0.802976 | 0.095 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 0.802976 | 0.095 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 0.802976 | 0.095 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 0.802976 | 0.095 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 0.802976 | 0.095 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 0.802976 | 0.095 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 0.806748 | 0.093 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 0.809011 | 0.092 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 0.810477 | 0.091 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 0.813044 | 0.090 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 0.813044 | 0.090 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 0.813044 | 0.090 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 0.813044 | 0.090 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 0.813044 | 0.090 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 0.814250 | 0.089 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 0.814250 | 0.089 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 0.815691 | 0.088 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 0.816545 | 0.088 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 0.819798 | 0.086 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 0.820333 | 0.086 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 0.821444 | 0.085 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 0.821491 | 0.085 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 0.822598 | 0.085 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 0.822598 | 0.085 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 0.822598 | 0.085 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 0.822598 | 0.085 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 0.822598 | 0.085 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 0.826864 | 0.083 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 0.827415 | 0.082 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 0.827415 | 0.082 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 0.828478 | 0.082 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 0.828478 | 0.082 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 0.831665 | 0.080 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 0.831665 | 0.080 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 0.831665 | 0.080 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 0.831665 | 0.080 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 0.831665 | 0.080 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 0.831665 | 0.080 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 0.831665 | 0.080 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 0.833213 | 0.079 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 0.840269 | 0.076 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 0.840269 | 0.076 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 0.840269 | 0.076 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 0.840269 | 0.076 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 0.840269 | 0.076 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 0.840269 | 0.076 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 0.841717 | 0.075 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 0.841717 | 0.075 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 0.848433 | 0.071 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 0.848433 | 0.071 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 0.848433 | 0.071 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 0.849613 | 0.071 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 0.854023 | 0.069 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 0.856117 | 0.067 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 0.856181 | 0.067 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 0.859750 | 0.066 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 0.859843 | 0.066 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 0.859843 | 0.066 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 0.863533 | 0.064 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 0.863533 | 0.064 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 0.863533 | 0.064 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 0.864556 | 0.063 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 0.865449 | 0.063 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 0.865449 | 0.063 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 0.865680 | 0.063 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 0.870509 | 0.060 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 0.870509 | 0.060 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 0.870509 | 0.060 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 0.870509 | 0.060 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 0.873193 | 0.059 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 0.873832 | 0.059 | 0 | 0 |
| CS/DS degradation | R-HSA-2024101 | 0.877130 | 0.057 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 0.877130 | 0.057 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 0.877130 | 0.057 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 0.877130 | 0.057 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 0.877752 | 0.057 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 0.878223 | 0.056 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 0.879384 | 0.056 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 0.879384 | 0.056 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 0.881057 | 0.055 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 0.882511 | 0.054 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 0.883412 | 0.054 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 0.883412 | 0.054 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 0.883412 | 0.054 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 0.883412 | 0.054 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 0.883412 | 0.054 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 0.883412 | 0.054 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 0.883412 | 0.054 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 0.883412 | 0.054 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 0.888492 | 0.051 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 0.888492 | 0.051 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 0.889373 | 0.051 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 0.889373 | 0.051 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 0.889373 | 0.051 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 0.889373 | 0.051 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 0.890654 | 0.050 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 0.894976 | 0.048 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 0.895030 | 0.048 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 0.895030 | 0.048 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 0.895030 | 0.048 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 0.895030 | 0.048 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 0.895030 | 0.048 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 0.895030 | 0.048 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 0.897647 | 0.047 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 0.897805 | 0.047 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 0.898288 | 0.047 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 0.898288 | 0.047 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 0.899829 | 0.046 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 0.900398 | 0.046 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 0.900398 | 0.046 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 0.901923 | 0.045 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 0.903398 | 0.044 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 0.905492 | 0.043 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 0.910325 | 0.041 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 0.910325 | 0.041 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 0.910325 | 0.041 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 0.910325 | 0.041 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 0.910325 | 0.041 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 0.910325 | 0.041 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 0.913295 | 0.039 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 0.913295 | 0.039 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 0.913295 | 0.039 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 0.914912 | 0.039 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 0.914912 | 0.039 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 0.914912 | 0.039 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 0.915315 | 0.038 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 0.915315 | 0.038 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 0.915315 | 0.038 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 0.918070 | 0.037 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 0.918381 | 0.037 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 0.919264 | 0.037 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 0.919264 | 0.037 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 0.919264 | 0.037 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 0.919264 | 0.037 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 0.921770 | 0.035 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 0.923394 | 0.035 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 0.923394 | 0.035 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 0.923394 | 0.035 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 0.923394 | 0.035 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 0.923394 | 0.035 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 0.925717 | 0.034 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 0.927313 | 0.033 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 0.927313 | 0.033 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 0.927611 | 0.033 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 0.929707 | 0.032 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 0.930036 | 0.032 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 0.931032 | 0.031 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 0.931158 | 0.031 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 0.931158 | 0.031 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 0.934561 | 0.029 | 0 | 0 |
| Methylation | R-HSA-156581 | 0.934561 | 0.029 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 0.934561 | 0.029 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 0.934561 | 0.029 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 0.934561 | 0.029 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 0.934807 | 0.029 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 0.936814 | 0.028 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 0.937226 | 0.028 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 0.937909 | 0.028 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 0.939474 | 0.027 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 0.941086 | 0.026 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 0.941086 | 0.026 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 0.941086 | 0.026 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 0.941086 | 0.026 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 0.944304 | 0.025 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 0.945053 | 0.025 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 0.946099 | 0.024 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 0.946961 | 0.024 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 0.947805 | 0.023 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 0.949676 | 0.022 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 0.951106 | 0.022 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 0.952252 | 0.021 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 0.954696 | 0.020 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 0.954696 | 0.020 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 0.954696 | 0.020 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 0.957015 | 0.019 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 0.957244 | 0.019 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 0.959215 | 0.018 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 0.961433 | 0.017 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 0.962044 | 0.017 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 0.962794 | 0.016 | 0 | 0 |
| Chondroitin sulfate/dermatan sulfate metabolism | R-HSA-1793185 | 0.963284 | 0.016 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 0.963284 | 0.016 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 0.964228 | 0.016 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 0.964362 | 0.016 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 0.965164 | 0.015 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 0.965384 | 0.015 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 0.966948 | 0.015 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 0.967155 | 0.015 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 0.969939 | 0.013 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 0.969987 | 0.013 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 0.970068 | 0.013 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 0.970246 | 0.013 | 0 | 0 |
| Sialic acid metabolism | R-HSA-4085001 | 0.970246 | 0.013 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 0.970850 | 0.013 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 0.971770 | 0.012 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 0.971770 | 0.012 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 0.972496 | 0.012 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 0.972496 | 0.012 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 0.973216 | 0.012 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 0.973216 | 0.012 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 0.973216 | 0.012 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 0.973694 | 0.012 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 0.975899 | 0.011 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 0.975899 | 0.011 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 0.975941 | 0.011 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 0.975941 | 0.011 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 0.975941 | 0.011 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 0.978002 | 0.010 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 0.978002 | 0.010 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 0.979408 | 0.009 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 0.981464 | 0.008 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 0.982925 | 0.007 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 0.983210 | 0.007 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 0.983315 | 0.007 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 0.983315 | 0.007 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 0.984170 | 0.007 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 0.984170 | 0.007 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 0.984170 | 0.007 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 0.984170 | 0.007 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 0.985751 | 0.006 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 0.986482 | 0.006 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 0.986616 | 0.006 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 0.986652 | 0.006 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 0.987175 | 0.006 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 0.987175 | 0.006 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 0.987212 | 0.006 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 0.987711 | 0.005 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 0.988505 | 0.005 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 0.989346 | 0.005 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 0.989751 | 0.004 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 0.990648 | 0.004 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 0.991132 | 0.004 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 0.991132 | 0.004 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 0.991582 | 0.004 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 0.992477 | 0.003 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 0.993275 | 0.003 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 0.993531 | 0.003 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 0.993853 | 0.003 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 0.993863 | 0.003 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 0.994207 | 0.003 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 0.994476 | 0.002 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 0.994725 | 0.002 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 0.994760 | 0.002 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 0.994908 | 0.002 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 0.995284 | 0.002 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 0.995526 | 0.002 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 0.996327 | 0.002 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 0.996381 | 0.002 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 0.996906 | 0.001 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 0.997216 | 0.001 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 0.997228 | 0.001 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 0.997448 | 0.001 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 0.997448 | 0.001 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 0.997494 | 0.001 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 0.997513 | 0.001 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 0.997787 | 0.001 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 0.998075 | 0.001 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 0.998174 | 0.001 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 0.998351 | 0.001 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 0.998357 | 0.001 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 0.998422 | 0.001 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 0.998441 | 0.001 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 0.998940 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 0.998978 | 0.000 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 0.999023 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 0.999040 | 0.000 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 0.999102 | 0.000 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 0.999267 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 0.999285 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 0.999321 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 0.999330 | 0.000 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 0.999501 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 0.999561 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 0.999561 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 0.999669 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 0.999784 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 0.999791 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 0.999791 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 0.999798 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 0.999808 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 0.999812 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 0.999853 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 0.999855 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 0.999900 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 0.999926 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 0.999948 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 0.999969 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 0.999987 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 0.999991 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 0.999999 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 0.999999 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000 | -0.000 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 1.000000 | 0.000 | 1 | 1 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 1.000000 | 0.000 | 1 | 1 |
| Signaling by Activin | R-HSA-1502540 | 1.000000 | 0.000 | 1 | 1 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cellular response to heat stress | R-HSA-3371556 | 9.992007e-16 | 15.000 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.332268e-15 | 14.875 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 5.551115e-15 | 14.256 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 2.320366e-14 | 13.634 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 1.182388e-13 | 12.927 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.251221e-13 | 12.903 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 4.767298e-13 | 12.322 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.425748e-12 | 11.846 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 2.466360e-12 | 11.608 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 4.818257e-12 | 11.317 | 0 | 0 |
| M Phase | R-HSA-68886 | 6.743162e-12 | 11.171 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 1.374156e-11 | 10.862 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 4.359435e-11 | 10.361 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 5.457546e-11 | 10.263 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 5.457546e-11 | 10.263 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.256835e-10 | 9.901 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 1.958489e-10 | 9.708 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 3.669879e-10 | 9.435 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 6.893324e-10 | 9.162 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 1.094815e-09 | 8.961 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.374108e-09 | 8.862 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.739002e-09 | 8.760 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 2.021729e-09 | 8.694 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 7.661266e-09 | 8.116 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 7.346179e-09 | 8.134 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 9.000901e-09 | 8.046 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 8.795074e-09 | 8.056 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.477690e-08 | 7.830 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 1.522990e-08 | 7.817 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.783369e-08 | 7.555 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 2.982255e-08 | 7.525 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 3.887649e-08 | 7.410 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 4.441500e-08 | 7.352 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 5.288985e-08 | 7.277 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 6.781865e-08 | 7.169 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 8.960759e-08 | 7.048 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 1.060805e-07 | 6.974 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 1.154454e-07 | 6.938 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 1.407270e-07 | 6.852 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.499044e-07 | 6.824 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.874612e-07 | 6.727 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 2.275823e-07 | 6.643 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 2.361270e-07 | 6.627 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 2.632839e-07 | 6.580 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 3.341624e-07 | 6.476 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 3.527742e-07 | 6.453 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 6.798410e-07 | 6.168 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 6.789537e-07 | 6.168 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 7.984401e-07 | 6.098 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 8.660557e-07 | 6.062 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 9.224105e-07 | 6.035 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.075306e-06 | 5.968 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.283346e-06 | 5.892 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 1.492618e-06 | 5.826 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.509332e-06 | 5.821 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.747169e-06 | 5.758 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 2.403165e-06 | 5.619 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 2.526027e-06 | 5.598 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 2.480084e-06 | 5.606 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 2.832987e-06 | 5.548 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 3.087207e-06 | 5.510 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 4.334281e-06 | 5.363 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 4.757725e-06 | 5.323 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 4.800378e-06 | 5.319 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 5.006325e-06 | 5.300 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 5.531396e-06 | 5.257 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 6.513745e-06 | 5.186 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 8.235610e-06 | 5.084 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 9.022093e-06 | 5.045 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 9.976757e-06 | 5.001 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 1.147135e-05 | 4.940 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 1.374385e-05 | 4.862 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 1.399153e-05 | 4.854 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 1.474872e-05 | 4.831 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 1.807583e-05 | 4.743 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 1.807583e-05 | 4.743 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.860904e-05 | 4.730 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 2.029264e-05 | 4.693 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 2.102057e-05 | 4.677 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 2.594920e-05 | 4.586 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 2.577155e-05 | 4.589 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 2.581599e-05 | 4.588 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 2.696320e-05 | 4.569 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 2.987983e-05 | 4.525 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 3.143127e-05 | 4.503 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 3.674596e-05 | 4.435 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 4.015159e-05 | 4.396 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 4.494785e-05 | 4.347 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 5.207698e-05 | 4.283 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 5.383245e-05 | 4.269 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 5.575329e-05 | 4.254 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 6.511125e-05 | 4.186 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 7.247826e-05 | 4.140 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 8.183912e-05 | 4.087 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 7.800426e-05 | 4.108 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 8.560232e-05 | 4.068 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 9.263147e-05 | 4.033 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 9.318287e-05 | 4.031 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 9.830722e-05 | 4.007 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.205661e-04 | 3.919 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 1.327278e-04 | 3.877 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 1.327278e-04 | 3.877 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 1.332656e-04 | 3.875 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 1.348249e-04 | 3.870 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 1.348249e-04 | 3.870 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 1.352775e-04 | 3.869 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 1.474730e-04 | 3.831 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 1.472268e-04 | 3.832 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.532390e-04 | 3.815 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.532390e-04 | 3.815 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 1.653779e-04 | 3.782 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 1.994804e-04 | 3.700 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 1.994804e-04 | 3.700 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 2.029484e-04 | 3.693 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.952752e-04 | 3.709 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.952752e-04 | 3.709 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 2.221988e-04 | 3.653 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 2.255154e-04 | 3.647 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 2.128954e-04 | 3.672 | 0 | 0 |
| S Phase | R-HSA-69242 | 2.121266e-04 | 3.673 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.113434e-04 | 3.675 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 2.112841e-04 | 3.675 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 2.216857e-04 | 3.654 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 2.112841e-04 | 3.675 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 2.651641e-04 | 3.576 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 2.766744e-04 | 3.558 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 2.794785e-04 | 3.554 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 2.832332e-04 | 3.548 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 3.289730e-04 | 3.483 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 3.575558e-04 | 3.447 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 3.602845e-04 | 3.443 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 3.782148e-04 | 3.422 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 4.254184e-04 | 3.371 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 4.363014e-04 | 3.360 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 5.014135e-04 | 3.300 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 5.240883e-04 | 3.281 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 5.280969e-04 | 3.277 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 5.381551e-04 | 3.269 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 5.622799e-04 | 3.250 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 5.987053e-04 | 3.223 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 5.912836e-04 | 3.228 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 6.042157e-04 | 3.219 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 6.252309e-04 | 3.204 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 6.388024e-04 | 3.195 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 6.540313e-04 | 3.184 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 6.561430e-04 | 3.183 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 6.975133e-04 | 3.156 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 7.027089e-04 | 3.153 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 7.027089e-04 | 3.153 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 7.027089e-04 | 3.153 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 7.027089e-04 | 3.153 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 7.193236e-04 | 3.143 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 7.372960e-04 | 3.132 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 7.646777e-04 | 3.117 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 8.869136e-04 | 3.052 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 8.869136e-04 | 3.052 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 8.869136e-04 | 3.052 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 8.869136e-04 | 3.052 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 8.869136e-04 | 3.052 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 8.869136e-04 | 3.052 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 8.869136e-04 | 3.052 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 8.869136e-04 | 3.052 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 8.869136e-04 | 3.052 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 8.869136e-04 | 3.052 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 8.869136e-04 | 3.052 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 8.442425e-04 | 3.074 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 8.442425e-04 | 3.074 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 8.984018e-04 | 3.047 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 9.210012e-04 | 3.036 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.018894e-03 | 2.992 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 1.081483e-03 | 2.966 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 9.931097e-04 | 3.003 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 1.107733e-03 | 2.956 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 1.134593e-03 | 2.945 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.150427e-03 | 2.939 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 1.160379e-03 | 2.935 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 1.160379e-03 | 2.935 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 1.161160e-03 | 2.935 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 1.235118e-03 | 2.908 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 1.328262e-03 | 2.877 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 1.341656e-03 | 2.872 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 1.365342e-03 | 2.865 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 1.394102e-03 | 2.856 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.449011e-03 | 2.839 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.565175e-03 | 2.805 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.455673e-03 | 2.837 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 1.462624e-03 | 2.835 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.576141e-03 | 2.802 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 1.502360e-03 | 2.823 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 1.590519e-03 | 2.798 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.595883e-03 | 2.797 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 1.632036e-03 | 2.787 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.637355e-03 | 2.786 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 1.655814e-03 | 2.781 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 1.655814e-03 | 2.781 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 1.668477e-03 | 2.778 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.822156e-03 | 2.739 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 1.875386e-03 | 2.727 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.884243e-03 | 2.725 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.884243e-03 | 2.725 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 1.884243e-03 | 2.725 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 1.919431e-03 | 2.717 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.919431e-03 | 2.717 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 1.919431e-03 | 2.717 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 1.953275e-03 | 2.709 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 1.953275e-03 | 2.709 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 2.008500e-03 | 2.697 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.070874e-03 | 2.684 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 2.284501e-03 | 2.641 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 2.266077e-03 | 2.645 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 2.287082e-03 | 2.641 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 2.267281e-03 | 2.644 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.418067e-03 | 2.617 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 2.267800e-03 | 2.644 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 2.517308e-03 | 2.599 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 2.518400e-03 | 2.599 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 2.540299e-03 | 2.595 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 2.540299e-03 | 2.595 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 2.635728e-03 | 2.579 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 2.659270e-03 | 2.575 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 2.659270e-03 | 2.575 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 2.659270e-03 | 2.575 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 2.707777e-03 | 2.567 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 2.710650e-03 | 2.567 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 2.733055e-03 | 2.563 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 2.754180e-03 | 2.560 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 2.763138e-03 | 2.559 | 1 | 0 |
| Macroautophagy | R-HSA-1632852 | 2.924675e-03 | 2.534 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 2.955598e-03 | 2.529 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 3.056699e-03 | 2.515 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 3.056699e-03 | 2.515 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 3.056699e-03 | 2.515 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 3.203731e-03 | 2.494 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 3.306794e-03 | 2.481 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 3.348238e-03 | 2.475 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 3.348238e-03 | 2.475 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 4.175013e-03 | 2.379 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 4.175013e-03 | 2.379 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 4.175013e-03 | 2.379 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 4.119963e-03 | 2.385 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 3.685275e-03 | 2.434 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 3.685275e-03 | 2.434 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 3.768616e-03 | 2.424 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 4.068411e-03 | 2.391 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 4.119963e-03 | 2.385 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 3.768616e-03 | 2.424 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 3.667563e-03 | 2.436 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 3.825386e-03 | 2.417 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 3.750362e-03 | 2.426 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 3.802939e-03 | 2.420 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 4.227689e-03 | 2.374 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 4.244868e-03 | 2.372 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 4.255263e-03 | 2.371 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 4.379784e-03 | 2.359 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 4.449613e-03 | 2.352 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 4.449613e-03 | 2.352 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 4.580247e-03 | 2.339 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 4.885393e-03 | 2.311 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 4.885393e-03 | 2.311 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 5.185236e-03 | 2.285 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 5.225679e-03 | 2.282 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 5.282661e-03 | 2.277 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 5.282661e-03 | 2.277 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 5.289732e-03 | 2.277 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 5.289732e-03 | 2.277 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 5.477342e-03 | 2.261 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 5.611814e-03 | 2.251 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 5.611814e-03 | 2.251 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 5.830896e-03 | 2.234 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 5.851465e-03 | 2.233 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 5.893375e-03 | 2.230 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 5.893375e-03 | 2.230 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 6.302140e-03 | 2.201 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 7.062319e-03 | 2.151 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 7.119556e-03 | 2.148 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 6.084848e-03 | 2.216 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 7.062319e-03 | 2.151 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 6.520126e-03 | 2.186 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 6.209133e-03 | 2.207 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 6.520126e-03 | 2.186 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 7.119612e-03 | 2.148 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 6.344593e-03 | 2.198 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 7.150891e-03 | 2.146 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 7.099208e-03 | 2.149 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 7.099208e-03 | 2.149 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 7.299673e-03 | 2.137 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 7.299673e-03 | 2.137 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 7.324247e-03 | 2.135 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 7.718368e-03 | 2.112 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 7.797476e-03 | 2.108 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 7.797476e-03 | 2.108 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 8.035804e-03 | 2.095 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 8.035804e-03 | 2.095 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 8.102301e-03 | 2.091 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 8.102301e-03 | 2.091 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 8.215520e-03 | 2.085 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 8.323806e-03 | 2.080 | 0 | 0 |
| Depurination | R-HSA-73927 | 8.534021e-03 | 2.069 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 8.587762e-03 | 2.066 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 8.587762e-03 | 2.066 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 8.956503e-03 | 2.048 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 8.956503e-03 | 2.048 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 8.956503e-03 | 2.048 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 8.963957e-03 | 2.048 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 9.065659e-03 | 2.043 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 9.464515e-03 | 2.024 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 9.602021e-03 | 2.018 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 1.026215e-02 | 1.989 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 1.229612e-02 | 1.910 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.220157e-02 | 1.914 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.121611e-02 | 1.950 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 9.921846e-03 | 2.003 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.202845e-02 | 1.920 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 1.219963e-02 | 1.914 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 1.196477e-02 | 1.922 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 1.240061e-02 | 1.907 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 1.152746e-02 | 1.938 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 1.107292e-02 | 1.956 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.070223e-02 | 1.971 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 1.212944e-02 | 1.916 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.006896e-02 | 1.997 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 9.999208e-03 | 2.000 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 9.999208e-03 | 2.000 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 1.220157e-02 | 1.914 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 1.196477e-02 | 1.922 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 1.045771e-02 | 1.981 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.106433e-02 | 1.956 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 1.152746e-02 | 1.938 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.196477e-02 | 1.922 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 1.026215e-02 | 1.989 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 1.148200e-02 | 1.940 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 9.921846e-03 | 2.003 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 1.220157e-02 | 1.914 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 1.178617e-02 | 1.929 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 1.121611e-02 | 1.950 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 9.924098e-03 | 2.003 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 1.148200e-02 | 1.940 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 1.229612e-02 | 1.910 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 1.026215e-02 | 1.989 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 1.026215e-02 | 1.989 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 1.026215e-02 | 1.989 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 1.303756e-02 | 1.885 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.321993e-02 | 1.879 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 1.350017e-02 | 1.870 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.362027e-02 | 1.866 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 1.366261e-02 | 1.864 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 1.368161e-02 | 1.864 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.370392e-02 | 1.863 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 1.373175e-02 | 1.862 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 1.391605e-02 | 1.856 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 1.422885e-02 | 1.847 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.438092e-02 | 1.842 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 1.444647e-02 | 1.840 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 1.485646e-02 | 1.828 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.489496e-02 | 1.827 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 1.517064e-02 | 1.819 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.549931e-02 | 1.810 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 1.549931e-02 | 1.810 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 1.549931e-02 | 1.810 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.549931e-02 | 1.810 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 1.549931e-02 | 1.810 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.549931e-02 | 1.810 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 1.583867e-02 | 1.800 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 1.609605e-02 | 1.793 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 1.639168e-02 | 1.785 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 1.650973e-02 | 1.782 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 1.683724e-02 | 1.774 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 1.683724e-02 | 1.774 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 1.683724e-02 | 1.774 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 1.685346e-02 | 1.773 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 1.690355e-02 | 1.772 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.690355e-02 | 1.772 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.690355e-02 | 1.772 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.734673e-02 | 1.761 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 1.734673e-02 | 1.761 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 1.805248e-02 | 1.743 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 1.817678e-02 | 1.740 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 1.848914e-02 | 1.733 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 1.851947e-02 | 1.732 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 1.851947e-02 | 1.732 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 1.864583e-02 | 1.729 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.866754e-02 | 1.729 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.866754e-02 | 1.729 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 1.866754e-02 | 1.729 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 1.876778e-02 | 1.727 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 1.936761e-02 | 1.713 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 1.936761e-02 | 1.713 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 1.936761e-02 | 1.713 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 1.936761e-02 | 1.713 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 1.958670e-02 | 1.708 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 2.031112e-02 | 1.692 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 2.051854e-02 | 1.688 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 2.538176e-02 | 1.595 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 2.708911e-02 | 1.567 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 2.708911e-02 | 1.567 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 2.708911e-02 | 1.567 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 2.708911e-02 | 1.567 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 2.384589e-02 | 1.623 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 2.384589e-02 | 1.623 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 2.437362e-02 | 1.613 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 2.437362e-02 | 1.613 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 2.264681e-02 | 1.645 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 2.264681e-02 | 1.645 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 2.603432e-02 | 1.584 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 2.544410e-02 | 1.594 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 2.544410e-02 | 1.594 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 2.530140e-02 | 1.597 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 2.701798e-02 | 1.568 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 2.321514e-02 | 1.634 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 2.739183e-02 | 1.562 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 2.516836e-02 | 1.599 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 2.708911e-02 | 1.567 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 2.769459e-02 | 1.558 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 2.739183e-02 | 1.562 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 2.130526e-02 | 1.672 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 2.380257e-02 | 1.623 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 2.810362e-02 | 1.551 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 2.361968e-02 | 1.627 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 2.437362e-02 | 1.613 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 2.544410e-02 | 1.594 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 2.120068e-02 | 1.674 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 2.708911e-02 | 1.567 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 2.739183e-02 | 1.562 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.264681e-02 | 1.645 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 2.603432e-02 | 1.584 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 2.313545e-02 | 1.636 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 2.822777e-02 | 1.549 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 2.822777e-02 | 1.549 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 2.822777e-02 | 1.549 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 2.822777e-02 | 1.549 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 2.822777e-02 | 1.549 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 2.287069e-02 | 1.641 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 2.686371e-02 | 1.571 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 2.834019e-02 | 1.548 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 2.834019e-02 | 1.548 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 2.856898e-02 | 1.544 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 2.884651e-02 | 1.540 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 2.884651e-02 | 1.540 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 2.886342e-02 | 1.540 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 2.886342e-02 | 1.540 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 2.886342e-02 | 1.540 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 2.886342e-02 | 1.540 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 2.896902e-02 | 1.538 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 2.934110e-02 | 1.533 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 2.937838e-02 | 1.532 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 2.955809e-02 | 1.529 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 2.976507e-02 | 1.526 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 2.976507e-02 | 1.526 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 2.984423e-02 | 1.525 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 3.019443e-02 | 1.520 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 3.092794e-02 | 1.510 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 3.092794e-02 | 1.510 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 3.143484e-02 | 1.503 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 3.146777e-02 | 1.502 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 3.200614e-02 | 1.495 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 3.202964e-02 | 1.494 | 0 | 0 |
| Translation | R-HSA-72766 | 3.238065e-02 | 1.490 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 3.302208e-02 | 1.481 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 3.378490e-02 | 1.471 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 3.385382e-02 | 1.470 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 3.385382e-02 | 1.470 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 3.476678e-02 | 1.459 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 3.477404e-02 | 1.459 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 3.520984e-02 | 1.453 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 3.687402e-02 | 1.433 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 3.719590e-02 | 1.430 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 3.739492e-02 | 1.427 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 3.739492e-02 | 1.427 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 3.739492e-02 | 1.427 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 3.739492e-02 | 1.427 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 3.776543e-02 | 1.423 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 3.776543e-02 | 1.423 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 3.831414e-02 | 1.417 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 3.845169e-02 | 1.415 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 3.845169e-02 | 1.415 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 3.857307e-02 | 1.414 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 3.857307e-02 | 1.414 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 3.946779e-02 | 1.404 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 3.946779e-02 | 1.404 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 4.056493e-02 | 1.392 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 4.126350e-02 | 1.384 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 4.126350e-02 | 1.384 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 4.142330e-02 | 1.383 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 4.195466e-02 | 1.377 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 4.195466e-02 | 1.377 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.232397e-02 | 1.373 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 4.343993e-02 | 1.362 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 4.356392e-02 | 1.361 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 6.561994e-02 | 1.183 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 6.561994e-02 | 1.183 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 6.561994e-02 | 1.183 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 6.561994e-02 | 1.183 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 5.181237e-02 | 1.286 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 4.807131e-02 | 1.318 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 4.807131e-02 | 1.318 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 5.002386e-02 | 1.301 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 4.847779e-02 | 1.314 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 4.847779e-02 | 1.314 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 4.847779e-02 | 1.314 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 4.847779e-02 | 1.314 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 4.847779e-02 | 1.314 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 4.548584e-02 | 1.342 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 5.942349e-02 | 1.226 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 5.942349e-02 | 1.226 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 5.376142e-02 | 1.270 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 5.403963e-02 | 1.267 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 4.645954e-02 | 1.333 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 6.491600e-02 | 1.188 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 4.732983e-02 | 1.325 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 5.552984e-02 | 1.255 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 5.052309e-02 | 1.297 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 6.249275e-02 | 1.204 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 5.642241e-02 | 1.249 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 6.391620e-02 | 1.194 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 6.391620e-02 | 1.194 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 6.391620e-02 | 1.194 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 5.830742e-02 | 1.234 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 4.807131e-02 | 1.318 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 6.510423e-02 | 1.186 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 4.762002e-02 | 1.322 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 5.349591e-02 | 1.272 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 6.399575e-02 | 1.194 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 4.807131e-02 | 1.318 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 5.468228e-02 | 1.262 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 5.997293e-02 | 1.222 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 5.649936e-02 | 1.248 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 5.649936e-02 | 1.248 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 4.756671e-02 | 1.323 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 5.774172e-02 | 1.239 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 5.002386e-02 | 1.301 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 5.642241e-02 | 1.249 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 5.376142e-02 | 1.270 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 5.830742e-02 | 1.234 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 5.346716e-02 | 1.272 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 5.346716e-02 | 1.272 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 5.346716e-02 | 1.272 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 5.346716e-02 | 1.272 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 6.050838e-02 | 1.218 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 5.361646e-02 | 1.271 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 5.642241e-02 | 1.249 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 6.038746e-02 | 1.219 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 4.756671e-02 | 1.323 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 5.901085e-02 | 1.229 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 5.234347e-02 | 1.281 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 5.997293e-02 | 1.222 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 6.510423e-02 | 1.186 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 5.002386e-02 | 1.301 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 5.942349e-02 | 1.226 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 6.041362e-02 | 1.219 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 6.032603e-02 | 1.219 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 5.002386e-02 | 1.301 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 5.618126e-02 | 1.250 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 4.744084e-02 | 1.324 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 6.575613e-02 | 1.182 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 6.656550e-02 | 1.177 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 6.656550e-02 | 1.177 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 6.656550e-02 | 1.177 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 6.728273e-02 | 1.172 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 6.750434e-02 | 1.171 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 6.750434e-02 | 1.171 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 6.750434e-02 | 1.171 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 6.795114e-02 | 1.168 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 6.844206e-02 | 1.165 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 7.013528e-02 | 1.154 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 7.013528e-02 | 1.154 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 7.013528e-02 | 1.154 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 7.013528e-02 | 1.154 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 7.033709e-02 | 1.153 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 7.129319e-02 | 1.147 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 7.129319e-02 | 1.147 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 7.149897e-02 | 1.146 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 7.284926e-02 | 1.138 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 7.284926e-02 | 1.138 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 7.329565e-02 | 1.135 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 7.345901e-02 | 1.134 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 7.345901e-02 | 1.134 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 7.345901e-02 | 1.134 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 7.452429e-02 | 1.128 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 7.452429e-02 | 1.128 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 7.511583e-02 | 1.124 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 7.511583e-02 | 1.124 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 7.511583e-02 | 1.124 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 7.572195e-02 | 1.121 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 7.572195e-02 | 1.121 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 7.572195e-02 | 1.121 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 7.572195e-02 | 1.121 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 7.627041e-02 | 1.118 | 1 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 7.652922e-02 | 1.116 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 7.782739e-02 | 1.109 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 8.077685e-02 | 1.093 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 8.077685e-02 | 1.093 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 8.083458e-02 | 1.092 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 8.134216e-02 | 1.090 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 8.163214e-02 | 1.088 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 8.163214e-02 | 1.088 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 8.322323e-02 | 1.080 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 8.467794e-02 | 1.072 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 8.476122e-02 | 1.072 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 8.476122e-02 | 1.072 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 8.476122e-02 | 1.072 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 8.724678e-02 | 1.059 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 8.724678e-02 | 1.059 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 8.724678e-02 | 1.059 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 8.724678e-02 | 1.059 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 8.724678e-02 | 1.059 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 8.724678e-02 | 1.059 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 8.730697e-02 | 1.059 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 8.730697e-02 | 1.059 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 8.730697e-02 | 1.059 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 8.730697e-02 | 1.059 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 8.851976e-02 | 1.053 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 9.182540e-02 | 1.037 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 9.182540e-02 | 1.037 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.182540e-02 | 1.037 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 9.406448e-02 | 1.027 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 9.406448e-02 | 1.027 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 9.438923e-02 | 1.025 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 9.438923e-02 | 1.025 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 9.438923e-02 | 1.025 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 9.555509e-02 | 1.020 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 9.594956e-02 | 1.018 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 9.641779e-02 | 1.016 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.668674e-02 | 1.015 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 9.734167e-02 | 1.012 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 9.750164e-02 | 1.011 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 9.750164e-02 | 1.011 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 9.782894e-02 | 1.010 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects | R-HSA-9646304 | 9.856984e-02 | 1.006 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 9.856984e-02 | 1.006 | 0 | 0 |
| Deletions in the AMER1 gene destabilize the destruction complex | R-HSA-5467343 | 9.856984e-02 | 1.006 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p14ARF Defects | R-HSA-9646303 | 9.856984e-02 | 1.006 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 9.856984e-02 | 1.006 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 9.856984e-02 | 1.006 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 1.009188e-01 | 0.996 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.021142e-01 | 0.991 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.029046e-01 | 0.988 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 1.029046e-01 | 0.988 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.033949e-01 | 0.986 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 1.038979e-01 | 0.983 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.045982e-01 | 0.980 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 1.052750e-01 | 0.978 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 1.052750e-01 | 0.978 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 1.052750e-01 | 0.978 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 1.071027e-01 | 0.970 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 1.071405e-01 | 0.970 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.071405e-01 | 0.970 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 1.074025e-01 | 0.969 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 1.093838e-01 | 0.961 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 1.093838e-01 | 0.961 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 1.093838e-01 | 0.961 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 1.107801e-01 | 0.956 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 1.153769e-01 | 0.938 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 1.153769e-01 | 0.938 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 1.153769e-01 | 0.938 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 1.153769e-01 | 0.938 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 1.153769e-01 | 0.938 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.874289e-01 | 0.727 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 1.874289e-01 | 0.727 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.874289e-01 | 0.727 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.874289e-01 | 0.727 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 1.874289e-01 | 0.727 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 1.874289e-01 | 0.727 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 1.874289e-01 | 0.727 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9630791 | 1.874289e-01 | 0.727 | 0 | 0 |
| Hereditary fructose intolerance | R-HSA-5657560 | 1.874289e-01 | 0.727 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 1.874289e-01 | 0.727 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9632697 | 1.874289e-01 | 0.727 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 1.874289e-01 | 0.727 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.874289e-01 | 0.727 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.874289e-01 | 0.727 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 1.293800e-01 | 0.888 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 1.293800e-01 | 0.888 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.293800e-01 | 0.888 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.293800e-01 | 0.888 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 1.293800e-01 | 0.888 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.650061e-01 | 0.782 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 1.650061e-01 | 0.782 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 1.304042e-01 | 0.885 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.304042e-01 | 0.885 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 2.020709e-01 | 0.694 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 2.020709e-01 | 0.694 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 2.020709e-01 | 0.694 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 1.542552e-01 | 0.812 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 1.542552e-01 | 0.812 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 1.216087e-01 | 0.915 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 1.566228e-01 | 0.805 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 1.566228e-01 | 0.805 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.566228e-01 | 0.805 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 2.054216e-01 | 0.687 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 2.054216e-01 | 0.687 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 2.054216e-01 | 0.687 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 1.366391e-01 | 0.864 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 1.764606e-01 | 0.753 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 2.322942e-01 | 0.634 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 2.322942e-01 | 0.634 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 2.322942e-01 | 0.634 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 2.322942e-01 | 0.634 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.322942e-01 | 0.634 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 2.322942e-01 | 0.634 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.322942e-01 | 0.634 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.322942e-01 | 0.634 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.322942e-01 | 0.634 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.322942e-01 | 0.634 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 1.524439e-01 | 0.817 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 1.323509e-01 | 0.878 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.970921e-01 | 0.705 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 1.970921e-01 | 0.705 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.459228e-01 | 0.836 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 1.267113e-01 | 0.897 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.600974e-01 | 0.796 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 1.600974e-01 | 0.796 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 2.039390e-01 | 0.690 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 1.638627e-01 | 0.786 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.534681e-01 | 0.814 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 2.220766e-01 | 0.653 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.343723e-01 | 0.872 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 1.826701e-01 | 0.738 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 1.427416e-01 | 0.845 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 1.528564e-01 | 0.816 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.510472e-01 | 0.821 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 2.042694e-01 | 0.690 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 1.638627e-01 | 0.786 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 1.176497e-01 | 0.929 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 1.346380e-01 | 0.871 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 1.385841e-01 | 0.858 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 1.509754e-01 | 0.821 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 2.054216e-01 | 0.687 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.376841e-01 | 0.861 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 1.194139e-01 | 0.923 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 2.198510e-01 | 0.658 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.515707e-01 | 0.819 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.321165e-01 | 0.879 | 0 | 0 |
| Toxicity of botulinum toxin type G (botG) | R-HSA-5250989 | 1.650061e-01 | 0.782 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.542552e-01 | 0.812 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 1.689682e-01 | 0.772 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 2.058701e-01 | 0.686 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 1.183032e-01 | 0.927 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 1.335142e-01 | 0.874 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 1.323509e-01 | 0.878 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 1.385841e-01 | 0.858 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 1.826447e-01 | 0.738 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 1.376841e-01 | 0.861 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 1.376841e-01 | 0.861 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 1.901103e-01 | 0.721 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 1.652851e-01 | 0.782 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 1.162465e-01 | 0.935 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 1.575108e-01 | 0.803 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 1.575108e-01 | 0.803 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 2.322942e-01 | 0.634 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 2.031772e-01 | 0.692 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 2.125550e-01 | 0.673 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.437261e-01 | 0.842 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 2.094017e-01 | 0.679 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.563443e-01 | 0.806 | 0 | 0 |
| Pyrophosphate hydrolysis | R-HSA-71737 | 1.650061e-01 | 0.782 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 2.184101e-01 | 0.661 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 2.220766e-01 | 0.653 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 1.775521e-01 | 0.751 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 2.263701e-01 | 0.645 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 2.263701e-01 | 0.645 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 2.020709e-01 | 0.694 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 1.197462e-01 | 0.922 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 1.216087e-01 | 0.915 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 1.689682e-01 | 0.772 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 1.793373e-01 | 0.746 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 1.268673e-01 | 0.897 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 1.239782e-01 | 0.907 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.467976e-01 | 0.833 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 1.874289e-01 | 0.727 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 1.874289e-01 | 0.727 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 1.293800e-01 | 0.888 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 1.293800e-01 | 0.888 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.304042e-01 | 0.885 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.197462e-01 | 0.922 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 1.793361e-01 | 0.746 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 1.216087e-01 | 0.915 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 1.566228e-01 | 0.805 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 1.970921e-01 | 0.705 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 2.184101e-01 | 0.661 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 1.385841e-01 | 0.858 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 1.438096e-01 | 0.842 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.856835e-01 | 0.731 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 1.876913e-01 | 0.727 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 2.112805e-01 | 0.675 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 1.766062e-01 | 0.753 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 1.527861e-01 | 0.816 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 1.856835e-01 | 0.731 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.167754e-01 | 0.933 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 2.005183e-01 | 0.698 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 1.366391e-01 | 0.864 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.656543e-01 | 0.781 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 1.334349e-01 | 0.875 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 1.304042e-01 | 0.885 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 1.304042e-01 | 0.885 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 1.793361e-01 | 0.746 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 1.194139e-01 | 0.923 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.353600e-01 | 0.869 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 1.218424e-01 | 0.914 | 1 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 2.258394e-01 | 0.646 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.304042e-01 | 0.885 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 2.020709e-01 | 0.694 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 1.970921e-01 | 0.705 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 1.420520e-01 | 0.848 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 1.420520e-01 | 0.848 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.770719e-01 | 0.752 | 0 | 0 |
| Immune System | R-HSA-168256 | 1.556625e-01 | 0.808 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 2.251431e-01 | 0.648 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 1.437261e-01 | 0.842 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 1.216087e-01 | 0.915 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 1.385841e-01 | 0.858 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 1.642984e-01 | 0.784 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 1.910250e-01 | 0.719 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 2.222603e-01 | 0.653 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 1.772215e-01 | 0.751 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 1.855475e-01 | 0.732 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 1.454335e-01 | 0.837 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 1.669693e-01 | 0.777 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 1.293800e-01 | 0.888 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 1.267113e-01 | 0.897 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 1.861538e-01 | 0.730 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 1.165861e-01 | 0.933 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 2.220766e-01 | 0.653 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 1.891670e-01 | 0.723 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 1.748393e-01 | 0.757 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 1.442311e-01 | 0.841 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 1.261943e-01 | 0.899 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.793361e-01 | 0.746 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 1.287786e-01 | 0.890 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 1.376841e-01 | 0.861 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 2.199184e-01 | 0.658 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 1.335142e-01 | 0.874 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 1.991890e-01 | 0.701 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 2.039390e-01 | 0.690 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 2.039390e-01 | 0.690 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 1.366391e-01 | 0.864 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 1.323509e-01 | 0.878 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 2.240691e-01 | 0.650 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 1.650061e-01 | 0.782 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 1.764606e-01 | 0.753 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.184101e-01 | 0.661 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 1.542552e-01 | 0.812 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 1.420520e-01 | 0.848 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 1.566228e-01 | 0.805 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.346380e-01 | 0.871 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 1.970921e-01 | 0.705 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 2.331516e-01 | 0.632 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 2.372216e-01 | 0.625 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 2.386861e-01 | 0.622 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 2.386861e-01 | 0.622 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 2.399451e-01 | 0.620 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 2.399451e-01 | 0.620 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 2.399451e-01 | 0.620 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 2.399451e-01 | 0.620 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 2.399451e-01 | 0.620 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 2.399451e-01 | 0.620 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 2.399451e-01 | 0.620 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 2.399451e-01 | 0.620 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 2.399451e-01 | 0.620 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 2.399451e-01 | 0.620 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 2.399451e-01 | 0.620 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.403070e-01 | 0.619 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 2.403070e-01 | 0.619 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 2.403070e-01 | 0.619 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 2.403070e-01 | 0.619 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 2.410526e-01 | 0.618 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 2.410526e-01 | 0.618 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 2.410526e-01 | 0.618 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 2.500967e-01 | 0.602 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 2.532047e-01 | 0.597 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 2.532047e-01 | 0.597 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 2.555551e-01 | 0.593 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 2.583442e-01 | 0.588 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 2.597476e-01 | 0.585 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 2.597476e-01 | 0.585 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 2.597476e-01 | 0.585 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 2.597476e-01 | 0.585 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 2.597476e-01 | 0.585 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 2.597476e-01 | 0.585 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 2.602505e-01 | 0.585 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 2.602505e-01 | 0.585 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 2.602505e-01 | 0.585 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 2.602505e-01 | 0.585 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 2.626765e-01 | 0.581 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.626765e-01 | 0.581 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 2.626765e-01 | 0.581 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 2.639029e-01 | 0.579 | 0 | 0 |
| Protein folding | R-HSA-391251 | 2.663394e-01 | 0.575 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 2.675333e-01 | 0.573 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 2.675333e-01 | 0.573 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 2.675333e-01 | 0.573 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 2.675333e-01 | 0.573 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 2.675333e-01 | 0.573 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 2.675333e-01 | 0.573 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 2.675333e-01 | 0.573 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 2.675333e-01 | 0.573 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 2.675333e-01 | 0.573 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 2.675333e-01 | 0.573 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 2.675333e-01 | 0.573 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.697882e-01 | 0.569 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 2.729354e-01 | 0.564 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 2.781093e-01 | 0.556 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 2.781093e-01 | 0.556 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 2.781093e-01 | 0.556 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 2.781093e-01 | 0.556 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 2.781093e-01 | 0.556 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 2.781093e-01 | 0.556 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 2.781093e-01 | 0.556 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 2.781093e-01 | 0.556 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 2.781093e-01 | 0.556 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 2.795188e-01 | 0.554 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.797883e-01 | 0.553 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.797883e-01 | 0.553 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 2.797883e-01 | 0.553 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 2.797883e-01 | 0.553 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 2.847199e-01 | 0.546 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 2.854145e-01 | 0.545 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 2.854145e-01 | 0.545 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 2.868254e-01 | 0.542 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 2.875885e-01 | 0.541 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 2.894308e-01 | 0.538 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 2.948313e-01 | 0.530 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 2.975566e-01 | 0.526 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 2.975566e-01 | 0.526 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 2.975566e-01 | 0.526 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 2.995639e-01 | 0.524 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 2.996012e-01 | 0.523 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 3.084207e-01 | 0.511 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 3.152787e-01 | 0.501 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 3.156380e-01 | 0.501 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 3.156380e-01 | 0.501 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 3.161387e-01 | 0.500 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 3.161387e-01 | 0.500 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 3.161387e-01 | 0.500 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 3.161387e-01 | 0.500 | 0 | 0 |
| Toxicity of botulinum toxin type B (botB) | R-HSA-5250958 | 3.161387e-01 | 0.500 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 3.161387e-01 | 0.500 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 3.161387e-01 | 0.500 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 3.196256e-01 | 0.495 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 3.196256e-01 | 0.495 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 3.196256e-01 | 0.495 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 3.197523e-01 | 0.495 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 3.223522e-01 | 0.492 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 3.301992e-01 | 0.481 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 3.301992e-01 | 0.481 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 3.301992e-01 | 0.481 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 3.301992e-01 | 0.481 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 3.315986e-01 | 0.479 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 3.315986e-01 | 0.479 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 3.367854e-01 | 0.473 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 3.397452e-01 | 0.469 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 3.397452e-01 | 0.469 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 3.397452e-01 | 0.469 | 0 | 0 |
| Signalling to ERK5 | R-HSA-198765 | 3.397452e-01 | 0.469 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 3.397452e-01 | 0.469 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 3.397452e-01 | 0.469 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 3.397452e-01 | 0.469 | 0 | 0 |
| ATF6B (ATF6-beta) activates chaperones | R-HSA-8874177 | 3.397452e-01 | 0.469 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 3.397993e-01 | 0.469 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 3.437325e-01 | 0.464 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 3.437325e-01 | 0.464 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 3.442906e-01 | 0.463 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 3.442906e-01 | 0.463 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 3.451305e-01 | 0.462 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 3.478929e-01 | 0.459 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 3.536892e-01 | 0.451 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 3.536892e-01 | 0.451 | 0 | 0 |
| 5-Phosphoribose 1-diphosphate biosynthesis | R-HSA-73843 | 3.536892e-01 | 0.451 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 3.536892e-01 | 0.451 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 3.536892e-01 | 0.451 | 1 | 1 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 3.536892e-01 | 0.451 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 3.536892e-01 | 0.451 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 3.536892e-01 | 0.451 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 3.536892e-01 | 0.451 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 3.536892e-01 | 0.451 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 3.548569e-01 | 0.450 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 3.548569e-01 | 0.450 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 3.548569e-01 | 0.450 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 3.557549e-01 | 0.449 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 3.615980e-01 | 0.442 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 3.624653e-01 | 0.441 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 3.703149e-01 | 0.431 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 3.717242e-01 | 0.430 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 3.717242e-01 | 0.430 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 3.717242e-01 | 0.430 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 3.781096e-01 | 0.422 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 3.781096e-01 | 0.422 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 3.781096e-01 | 0.422 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 3.781096e-01 | 0.422 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 3.781096e-01 | 0.422 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 3.803574e-01 | 0.420 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 3.803574e-01 | 0.420 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.803574e-01 | 0.420 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 3.803574e-01 | 0.420 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 3.803574e-01 | 0.420 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 3.803574e-01 | 0.420 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 3.806890e-01 | 0.419 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 3.904858e-01 | 0.408 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 3.904858e-01 | 0.408 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 3.904858e-01 | 0.408 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 3.915734e-01 | 0.407 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 3.994805e-01 | 0.399 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 3.994805e-01 | 0.399 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 4.012766e-01 | 0.397 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 4.012766e-01 | 0.397 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 4.039974e-01 | 0.394 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 4.048418e-01 | 0.393 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 4.048418e-01 | 0.393 | 0 | 0 |
| Defective SLC7A7 causes lysinuric protein intolerance (LPI) | R-HSA-5660862 | 4.048418e-01 | 0.393 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 4.048418e-01 | 0.393 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 4.048418e-01 | 0.393 | 0 | 0 |
| Defective ABCC2 causes DJS | R-HSA-5679001 | 4.048418e-01 | 0.393 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 4.048418e-01 | 0.393 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 4.048418e-01 | 0.393 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 4.048418e-01 | 0.393 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 4.048418e-01 | 0.393 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 4.171232e-01 | 0.380 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 4.208265e-01 | 0.376 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 4.208265e-01 | 0.376 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 4.208265e-01 | 0.376 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 4.242837e-01 | 0.372 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 4.242837e-01 | 0.372 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 4.242837e-01 | 0.372 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 4.251772e-01 | 0.371 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 4.263124e-01 | 0.370 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 4.263124e-01 | 0.370 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 4.263124e-01 | 0.370 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 4.263124e-01 | 0.370 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 4.263124e-01 | 0.370 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 4.263124e-01 | 0.370 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 4.263124e-01 | 0.370 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 4.263124e-01 | 0.370 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 4.263124e-01 | 0.370 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 4.263124e-01 | 0.370 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 4.263124e-01 | 0.370 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 4.268844e-01 | 0.370 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 4.268844e-01 | 0.370 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 4.320928e-01 | 0.364 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 4.352577e-01 | 0.361 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 4.352577e-01 | 0.361 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 4.406238e-01 | 0.356 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 4.433650e-01 | 0.353 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 4.538334e-01 | 0.343 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.538334e-01 | 0.343 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 4.538334e-01 | 0.343 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 4.608033e-01 | 0.336 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 4.608033e-01 | 0.336 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 4.608033e-01 | 0.336 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 4.608033e-01 | 0.336 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 4.610026e-01 | 0.336 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 4.610026e-01 | 0.336 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 4.610026e-01 | 0.336 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 4.610026e-01 | 0.336 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 4.610026e-01 | 0.336 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 4.610026e-01 | 0.336 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 4.610026e-01 | 0.336 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 4.610026e-01 | 0.336 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 4.625302e-01 | 0.335 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 4.635237e-01 | 0.334 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 4.635237e-01 | 0.334 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 4.635237e-01 | 0.334 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 4.635237e-01 | 0.334 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 4.635237e-01 | 0.334 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 4.635237e-01 | 0.334 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 4.635237e-01 | 0.334 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 4.635237e-01 | 0.334 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 4.635237e-01 | 0.334 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 4.635237e-01 | 0.334 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 4.635237e-01 | 0.334 | 0 | 0 |
| Toxicity of tetanus toxin (tetX) | R-HSA-5250982 | 4.635237e-01 | 0.334 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 4.639838e-01 | 0.333 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 4.695519e-01 | 0.328 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 4.695519e-01 | 0.328 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 4.711852e-01 | 0.327 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 4.711852e-01 | 0.327 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 4.711852e-01 | 0.327 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 4.711852e-01 | 0.327 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 4.768217e-01 | 0.322 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 4.778362e-01 | 0.321 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 4.802388e-01 | 0.319 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 4.802388e-01 | 0.319 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 4.916954e-01 | 0.308 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 4.916954e-01 | 0.308 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 4.916954e-01 | 0.308 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 4.922136e-01 | 0.308 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 4.944323e-01 | 0.306 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 4.944323e-01 | 0.306 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 4.944323e-01 | 0.306 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 4.999359e-01 | 0.301 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 5.047504e-01 | 0.297 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 5.060253e-01 | 0.296 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 5.064457e-01 | 0.295 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 5.134436e-01 | 0.290 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 5.134436e-01 | 0.290 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 5.134436e-01 | 0.290 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 5.164228e-01 | 0.287 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 5.164228e-01 | 0.287 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 5.164228e-01 | 0.287 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 5.164228e-01 | 0.287 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 5.164228e-01 | 0.287 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 5.164228e-01 | 0.287 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 5.164228e-01 | 0.287 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 5.164228e-01 | 0.287 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 5.164228e-01 | 0.287 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 5.164228e-01 | 0.287 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 5.164228e-01 | 0.287 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 5.164228e-01 | 0.287 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 5.164228e-01 | 0.287 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 5.164228e-01 | 0.287 | 0 | 0 |
| Assembly of Viral Components at the Budding Site | R-HSA-168316 | 5.164228e-01 | 0.287 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 5.190902e-01 | 0.285 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 5.190902e-01 | 0.285 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 5.190902e-01 | 0.285 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 5.205636e-01 | 0.284 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 5.207515e-01 | 0.283 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 5.237542e-01 | 0.281 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 5.265129e-01 | 0.279 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 5.265129e-01 | 0.279 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 5.311299e-01 | 0.275 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 5.311603e-01 | 0.275 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 5.376522e-01 | 0.269 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 5.379256e-01 | 0.269 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 5.379256e-01 | 0.269 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 5.379256e-01 | 0.269 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 5.379256e-01 | 0.269 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 5.434938e-01 | 0.265 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 5.434938e-01 | 0.265 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 5.434938e-01 | 0.265 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 5.434938e-01 | 0.265 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 5.455732e-01 | 0.263 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 5.483894e-01 | 0.261 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 5.555008e-01 | 0.255 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 5.555008e-01 | 0.255 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 5.555008e-01 | 0.255 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 5.555838e-01 | 0.255 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 5.555838e-01 | 0.255 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 5.564130e-01 | 0.255 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 5.571853e-01 | 0.254 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 5.571853e-01 | 0.254 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 5.571853e-01 | 0.254 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 5.571853e-01 | 0.254 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 5.571853e-01 | 0.254 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 5.571853e-01 | 0.254 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 5.571853e-01 | 0.254 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 5.619727e-01 | 0.250 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 5.641086e-01 | 0.249 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 5.641086e-01 | 0.249 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 5.641086e-01 | 0.249 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 5.641086e-01 | 0.249 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 5.641086e-01 | 0.249 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 5.641086e-01 | 0.249 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 5.641086e-01 | 0.249 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 5.641086e-01 | 0.249 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 5.641086e-01 | 0.249 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 5.641086e-01 | 0.249 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 5.641086e-01 | 0.249 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 5.641086e-01 | 0.249 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 5.641086e-01 | 0.249 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 5.641086e-01 | 0.249 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 5.641086e-01 | 0.249 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 5.641086e-01 | 0.249 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 5.641086e-01 | 0.249 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 5.641086e-01 | 0.249 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 5.742229e-01 | 0.241 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 5.745267e-01 | 0.241 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 5.745267e-01 | 0.241 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 5.746907e-01 | 0.241 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 5.771706e-01 | 0.239 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 5.790968e-01 | 0.237 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 5.790968e-01 | 0.237 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 5.790968e-01 | 0.237 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 5.864155e-01 | 0.232 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 5.864155e-01 | 0.232 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 5.864155e-01 | 0.232 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 5.864155e-01 | 0.232 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 5.896385e-01 | 0.229 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 5.956876e-01 | 0.225 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 6.016362e-01 | 0.221 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 6.061419e-01 | 0.217 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 6.070946e-01 | 0.217 | 0 | 0 |
| Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) | R-HSA-5619070 | 6.070946e-01 | 0.217 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 6.070946e-01 | 0.217 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 6.070946e-01 | 0.217 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 6.070946e-01 | 0.217 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 6.070946e-01 | 0.217 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 6.070946e-01 | 0.217 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 6.070946e-01 | 0.217 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 6.095447e-01 | 0.215 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 6.141896e-01 | 0.212 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 6.141896e-01 | 0.212 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 6.141896e-01 | 0.212 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 6.149095e-01 | 0.211 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 6.149095e-01 | 0.211 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 6.149095e-01 | 0.211 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 6.149095e-01 | 0.211 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 6.183779e-01 | 0.209 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 6.220318e-01 | 0.206 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 6.224740e-01 | 0.206 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 6.238458e-01 | 0.205 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 6.258387e-01 | 0.204 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 6.264126e-01 | 0.203 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 6.293912e-01 | 0.201 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 6.371529e-01 | 0.196 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 6.394570e-01 | 0.194 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 6.396541e-01 | 0.194 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 6.405104e-01 | 0.193 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 6.405104e-01 | 0.193 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 6.405104e-01 | 0.193 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 6.405104e-01 | 0.193 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 6.458438e-01 | 0.190 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 6.458438e-01 | 0.190 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis | R-HSA-9632974 | 6.458438e-01 | 0.190 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 6.458438e-01 | 0.190 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 6.458438e-01 | 0.190 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 6.458438e-01 | 0.190 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 6.458438e-01 | 0.190 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 6.458438e-01 | 0.190 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 6.458438e-01 | 0.190 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 6.458438e-01 | 0.190 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 6.458438e-01 | 0.190 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 6.458438e-01 | 0.190 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 6.458438e-01 | 0.190 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 6.516012e-01 | 0.186 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 6.516128e-01 | 0.186 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 6.516147e-01 | 0.186 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 6.574324e-01 | 0.182 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 6.588646e-01 | 0.181 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 6.599086e-01 | 0.181 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 6.599086e-01 | 0.181 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 6.652208e-01 | 0.177 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 6.652208e-01 | 0.177 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 6.652208e-01 | 0.177 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 6.653944e-01 | 0.177 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 6.653944e-01 | 0.177 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 6.653944e-01 | 0.177 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 6.653944e-01 | 0.177 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 6.653944e-01 | 0.177 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 6.653944e-01 | 0.177 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 6.660324e-01 | 0.177 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 6.677620e-01 | 0.175 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 6.739336e-01 | 0.171 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 6.807735e-01 | 0.167 | 0 | 0 |
| RSK activation | R-HSA-444257 | 6.807735e-01 | 0.167 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 6.807735e-01 | 0.167 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 6.807735e-01 | 0.167 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 6.807735e-01 | 0.167 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 6.807735e-01 | 0.167 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 6.807735e-01 | 0.167 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 6.807735e-01 | 0.167 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 6.807735e-01 | 0.167 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 6.807735e-01 | 0.167 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 6.807735e-01 | 0.167 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 6.807735e-01 | 0.167 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 6.807735e-01 | 0.167 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 6.807735e-01 | 0.167 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 6.845189e-01 | 0.165 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 6.846254e-01 | 0.165 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 6.846254e-01 | 0.165 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 6.846254e-01 | 0.165 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 6.846533e-01 | 0.165 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 6.857464e-01 | 0.164 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 6.888690e-01 | 0.162 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 6.888690e-01 | 0.162 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 6.888690e-01 | 0.162 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 6.888690e-01 | 0.162 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 6.888690e-01 | 0.162 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 6.888690e-01 | 0.162 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 6.888690e-01 | 0.162 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 6.888690e-01 | 0.162 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 6.888690e-01 | 0.162 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 6.893111e-01 | 0.162 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 6.919656e-01 | 0.160 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 6.940792e-01 | 0.159 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 7.021030e-01 | 0.154 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 7.021030e-01 | 0.154 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 7.031768e-01 | 0.153 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 7.035735e-01 | 0.153 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 7.051810e-01 | 0.152 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 7.069742e-01 | 0.151 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 7.109701e-01 | 0.148 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 7.109701e-01 | 0.148 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 7.109701e-01 | 0.148 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 7.109701e-01 | 0.148 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 7.109701e-01 | 0.148 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 7.122600e-01 | 0.147 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 7.122600e-01 | 0.147 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 7.122600e-01 | 0.147 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 7.122600e-01 | 0.147 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 7.122600e-01 | 0.147 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 7.122600e-01 | 0.147 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 7.122600e-01 | 0.147 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 7.122600e-01 | 0.147 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 7.122600e-01 | 0.147 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 7.122600e-01 | 0.147 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 7.177103e-01 | 0.144 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 7.177103e-01 | 0.144 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 7.177103e-01 | 0.144 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 7.177103e-01 | 0.144 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 7.198345e-01 | 0.143 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 7.208826e-01 | 0.142 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 7.227015e-01 | 0.141 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 7.239192e-01 | 0.140 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 7.240296e-01 | 0.140 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 7.298380e-01 | 0.137 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 7.317402e-01 | 0.136 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 7.317402e-01 | 0.136 | 1 | 1 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 7.317402e-01 | 0.136 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 7.322976e-01 | 0.135 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 7.373616e-01 | 0.132 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 7.377544e-01 | 0.132 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 7.406426e-01 | 0.130 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 7.406426e-01 | 0.130 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 7.406426e-01 | 0.130 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 7.406426e-01 | 0.130 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 7.406426e-01 | 0.130 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 7.406426e-01 | 0.130 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 7.406426e-01 | 0.130 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 7.406426e-01 | 0.130 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 7.406426e-01 | 0.130 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 7.406426e-01 | 0.130 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 7.406426e-01 | 0.130 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 7.445915e-01 | 0.128 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 7.470944e-01 | 0.127 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 7.480178e-01 | 0.126 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 7.498725e-01 | 0.125 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 7.512269e-01 | 0.124 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 7.512269e-01 | 0.124 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 7.512269e-01 | 0.124 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 7.512269e-01 | 0.124 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 7.526827e-01 | 0.123 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 7.538073e-01 | 0.123 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 7.560322e-01 | 0.121 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 7.608828e-01 | 0.119 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 7.643842e-01 | 0.117 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 7.662270e-01 | 0.116 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 7.662270e-01 | 0.116 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 7.662270e-01 | 0.116 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 7.662270e-01 | 0.116 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 7.662270e-01 | 0.116 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 7.662270e-01 | 0.116 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 7.662270e-01 | 0.116 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 7.694811e-01 | 0.114 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 7.694811e-01 | 0.114 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 7.694811e-01 | 0.114 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 7.694811e-01 | 0.114 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 7.742594e-01 | 0.111 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 7.863901e-01 | 0.104 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 7.865563e-01 | 0.104 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 7.865563e-01 | 0.104 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 7.865563e-01 | 0.104 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 7.866960e-01 | 0.104 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 7.866960e-01 | 0.104 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 7.866960e-01 | 0.104 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 7.869558e-01 | 0.104 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 7.892890e-01 | 0.103 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 7.892890e-01 | 0.103 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 7.892890e-01 | 0.103 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 7.892890e-01 | 0.103 | 0 | 0 |
| Plasmalogen biosynthesis | R-HSA-75896 | 7.892890e-01 | 0.103 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 7.892890e-01 | 0.103 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 7.892890e-01 | 0.103 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 7.892890e-01 | 0.103 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 7.972434e-01 | 0.098 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 7.972434e-01 | 0.098 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 7.987945e-01 | 0.098 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 8.025074e-01 | 0.096 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 8.057023e-01 | 0.094 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 8.100771e-01 | 0.091 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 8.100771e-01 | 0.091 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 8.100771e-01 | 0.091 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 8.100771e-01 | 0.091 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 8.100771e-01 | 0.091 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 8.100771e-01 | 0.091 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 8.100771e-01 | 0.091 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 8.100771e-01 | 0.091 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 8.100771e-01 | 0.091 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 8.100771e-01 | 0.091 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 8.100771e-01 | 0.091 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 8.102217e-01 | 0.091 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 8.102217e-01 | 0.091 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 8.133301e-01 | 0.090 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 8.149625e-01 | 0.089 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 8.173901e-01 | 0.088 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 8.173901e-01 | 0.088 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 8.235217e-01 | 0.084 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 8.288154e-01 | 0.082 | 0 | 0 |
| Microbial factors inhibit CASP4 activity | R-HSA-9956593 | 8.288154e-01 | 0.082 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 8.288154e-01 | 0.082 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 8.288154e-01 | 0.082 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 8.288154e-01 | 0.082 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 8.288154e-01 | 0.082 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 8.288154e-01 | 0.082 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 8.288154e-01 | 0.082 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 8.312597e-01 | 0.080 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 8.312597e-01 | 0.080 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 8.312597e-01 | 0.080 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 8.312597e-01 | 0.080 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 8.314114e-01 | 0.080 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 8.316054e-01 | 0.080 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 8.316054e-01 | 0.080 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 8.326604e-01 | 0.080 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 8.330486e-01 | 0.079 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 8.395634e-01 | 0.076 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 8.416956e-01 | 0.075 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 8.441714e-01 | 0.074 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 8.450033e-01 | 0.073 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 8.457060e-01 | 0.073 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 8.457060e-01 | 0.073 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 8.457060e-01 | 0.073 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 8.457060e-01 | 0.073 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 8.457060e-01 | 0.073 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 8.457060e-01 | 0.073 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 8.457060e-01 | 0.073 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 8.457060e-01 | 0.073 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 8.457060e-01 | 0.073 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 8.503251e-01 | 0.070 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 8.503251e-01 | 0.070 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 8.509320e-01 | 0.070 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 8.517566e-01 | 0.070 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.553006e-01 | 0.068 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 8.553006e-01 | 0.068 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 8.564653e-01 | 0.067 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 8.609309e-01 | 0.065 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 8.609309e-01 | 0.065 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 8.609309e-01 | 0.065 | 1 | 1 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 8.609309e-01 | 0.065 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 8.609309e-01 | 0.065 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 8.609309e-01 | 0.065 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 8.609309e-01 | 0.065 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 8.609309e-01 | 0.065 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 8.649945e-01 | 0.063 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 8.649945e-01 | 0.063 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 8.664132e-01 | 0.062 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 8.669187e-01 | 0.062 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 8.673351e-01 | 0.062 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 8.673351e-01 | 0.062 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 8.673351e-01 | 0.062 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 8.673351e-01 | 0.062 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 8.673351e-01 | 0.062 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 8.733672e-01 | 0.059 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 8.738951e-01 | 0.059 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 8.746543e-01 | 0.058 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 8.746543e-01 | 0.058 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 8.746543e-01 | 0.058 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 8.746543e-01 | 0.058 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 8.746543e-01 | 0.058 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 8.746543e-01 | 0.058 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 8.746543e-01 | 0.058 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 8.746543e-01 | 0.058 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 8.746543e-01 | 0.058 | 0 | 0 |
| Virus Assembly and Release | R-HSA-168268 | 8.746543e-01 | 0.058 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 8.766145e-01 | 0.057 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 8.776909e-01 | 0.057 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 8.810184e-01 | 0.055 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 8.826791e-01 | 0.054 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 8.870242e-01 | 0.052 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 8.870242e-01 | 0.052 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 8.870242e-01 | 0.052 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 8.870242e-01 | 0.052 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 8.870242e-01 | 0.052 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 8.870242e-01 | 0.052 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 8.870242e-01 | 0.052 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 8.870242e-01 | 0.052 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 8.870242e-01 | 0.052 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 8.872957e-01 | 0.052 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 8.877951e-01 | 0.052 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 8.961967e-01 | 0.048 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 8.961967e-01 | 0.048 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 8.979690e-01 | 0.047 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 8.979690e-01 | 0.047 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 8.981740e-01 | 0.047 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 8.981740e-01 | 0.047 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 8.981740e-01 | 0.047 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 8.981740e-01 | 0.047 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 8.981740e-01 | 0.047 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 9.014306e-01 | 0.045 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.033384e-01 | 0.044 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.033384e-01 | 0.044 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 9.043905e-01 | 0.044 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 9.082240e-01 | 0.042 | 0 | 0 |
| PKA activation | R-HSA-163615 | 9.082240e-01 | 0.042 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 9.082240e-01 | 0.042 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 9.082240e-01 | 0.042 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 9.082240e-01 | 0.042 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.083432e-01 | 0.042 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.101067e-01 | 0.041 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 9.166918e-01 | 0.038 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.169046e-01 | 0.038 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 9.172826e-01 | 0.037 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 9.172826e-01 | 0.037 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 9.172826e-01 | 0.037 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.172826e-01 | 0.037 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 9.172826e-01 | 0.037 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.172826e-01 | 0.037 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 9.172826e-01 | 0.037 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.172826e-01 | 0.037 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.181670e-01 | 0.037 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.181670e-01 | 0.037 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.191201e-01 | 0.037 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 9.191201e-01 | 0.037 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 9.191201e-01 | 0.037 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 9.191201e-01 | 0.037 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.191201e-01 | 0.037 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.215564e-01 | 0.035 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.218556e-01 | 0.035 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.221709e-01 | 0.035 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 9.239664e-01 | 0.034 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 9.254476e-01 | 0.034 | 0 | 0 |
| Wax and plasmalogen biosynthesis | R-HSA-8848584 | 9.254476e-01 | 0.034 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 9.254476e-01 | 0.034 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.254476e-01 | 0.034 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.254476e-01 | 0.034 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 9.256384e-01 | 0.034 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.279335e-01 | 0.032 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.316584e-01 | 0.031 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 9.328071e-01 | 0.030 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 9.328071e-01 | 0.030 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 9.328071e-01 | 0.030 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.328071e-01 | 0.030 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 9.328071e-01 | 0.030 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 9.328071e-01 | 0.030 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.328071e-01 | 0.030 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 9.328071e-01 | 0.030 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.328071e-01 | 0.030 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 9.328071e-01 | 0.030 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.329606e-01 | 0.030 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.329606e-01 | 0.030 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.329606e-01 | 0.030 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.344500e-01 | 0.029 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 9.372151e-01 | 0.028 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.372151e-01 | 0.028 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.389786e-01 | 0.027 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.391405e-01 | 0.027 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.391762e-01 | 0.027 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 9.394404e-01 | 0.027 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 9.394404e-01 | 0.027 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 9.394404e-01 | 0.027 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.394404e-01 | 0.027 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 9.401283e-01 | 0.027 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.423411e-01 | 0.026 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 9.428864e-01 | 0.026 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.431028e-01 | 0.025 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 9.454193e-01 | 0.024 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 9.454193e-01 | 0.024 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.454193e-01 | 0.024 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 9.454193e-01 | 0.024 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 9.470673e-01 | 0.024 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.470673e-01 | 0.024 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.470673e-01 | 0.024 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.508082e-01 | 0.022 | 0 | 0 |
| ABC transporters in lipid homeostasis | R-HSA-1369062 | 9.508082e-01 | 0.022 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 9.508082e-01 | 0.022 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.508082e-01 | 0.022 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 9.508082e-01 | 0.022 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.508082e-01 | 0.022 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.514228e-01 | 0.022 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.554345e-01 | 0.020 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 9.556653e-01 | 0.020 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 9.556653e-01 | 0.020 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.556653e-01 | 0.020 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.556653e-01 | 0.020 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 9.556653e-01 | 0.020 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 9.556653e-01 | 0.020 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 9.584136e-01 | 0.018 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.584136e-01 | 0.018 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.591280e-01 | 0.018 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.600431e-01 | 0.018 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 9.600431e-01 | 0.018 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 9.600431e-01 | 0.018 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 9.600431e-01 | 0.018 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.600431e-01 | 0.018 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.600431e-01 | 0.018 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.605613e-01 | 0.017 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.605663e-01 | 0.017 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.625269e-01 | 0.017 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 9.639889e-01 | 0.016 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.639889e-01 | 0.016 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 9.639889e-01 | 0.016 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.639889e-01 | 0.016 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 9.639889e-01 | 0.016 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 9.639889e-01 | 0.016 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 9.656533e-01 | 0.015 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.656533e-01 | 0.015 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.670439e-01 | 0.015 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 9.675452e-01 | 0.014 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 9.675452e-01 | 0.014 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.675452e-01 | 0.014 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.675452e-01 | 0.014 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 9.675452e-01 | 0.014 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 9.677814e-01 | 0.014 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.677814e-01 | 0.014 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.680692e-01 | 0.014 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.681585e-01 | 0.014 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.711700e-01 | 0.013 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 9.735974e-01 | 0.012 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.736394e-01 | 0.012 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 9.736394e-01 | 0.012 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.736394e-01 | 0.012 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 9.750757e-01 | 0.011 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.758268e-01 | 0.011 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.759454e-01 | 0.011 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 9.762262e-01 | 0.010 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 9.762431e-01 | 0.010 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 9.762431e-01 | 0.010 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.778565e-01 | 0.010 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.778735e-01 | 0.010 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.785898e-01 | 0.009 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.797554e-01 | 0.009 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 9.807048e-01 | 0.008 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 9.807048e-01 | 0.008 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.821367e-01 | 0.008 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.826110e-01 | 0.008 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 9.826489e-01 | 0.008 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.830558e-01 | 0.007 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 9.843290e-01 | 0.007 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.843290e-01 | 0.007 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.845051e-01 | 0.007 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.845051e-01 | 0.007 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.851361e-01 | 0.007 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.858773e-01 | 0.006 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.858773e-01 | 0.006 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 9.858773e-01 | 0.006 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 9.861388e-01 | 0.006 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.870507e-01 | 0.006 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.872728e-01 | 0.006 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.872728e-01 | 0.006 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.873678e-01 | 0.006 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.879736e-01 | 0.005 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.883592e-01 | 0.005 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.885290e-01 | 0.005 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.885304e-01 | 0.005 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.885304e-01 | 0.005 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.896638e-01 | 0.005 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.896638e-01 | 0.005 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.896638e-01 | 0.005 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.896638e-01 | 0.005 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.909040e-01 | 0.004 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.909780e-01 | 0.004 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.916261e-01 | 0.004 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 9.924356e-01 | 0.003 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.924780e-01 | 0.003 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.924780e-01 | 0.003 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.931335e-01 | 0.003 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.931833e-01 | 0.003 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.931833e-01 | 0.003 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 9.937330e-01 | 0.003 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 9.938571e-01 | 0.003 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 9.938571e-01 | 0.003 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 9.938571e-01 | 0.003 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.943603e-01 | 0.002 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.944643e-01 | 0.002 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.944643e-01 | 0.002 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.948316e-01 | 0.002 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.948491e-01 | 0.002 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 9.950116e-01 | 0.002 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.955048e-01 | 0.002 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.955048e-01 | 0.002 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.956661e-01 | 0.002 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.958593e-01 | 0.002 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.959493e-01 | 0.002 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 9.959493e-01 | 0.002 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.961343e-01 | 0.002 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 9.970360e-01 | 0.001 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.970360e-01 | 0.001 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.973291e-01 | 0.001 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.975079e-01 | 0.001 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.975079e-01 | 0.001 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.975933e-01 | 0.001 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 9.978313e-01 | 0.001 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.980760e-01 | 0.001 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.980760e-01 | 0.001 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.981884e-01 | 0.001 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.984410e-01 | 0.001 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.984664e-01 | 0.001 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.987038e-01 | 0.001 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.989093e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.989171e-01 | 0.000 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.989171e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.989543e-01 | 0.000 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.989686e-01 | 0.000 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.991076e-01 | 0.000 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.991508e-01 | 0.000 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.991508e-01 | 0.000 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.991508e-01 | 0.000 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.992349e-01 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.992514e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.993719e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.993788e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.993918e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.994403e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.994403e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.994869e-01 | 0.000 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.995786e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.995906e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.997123e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.997302e-01 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.997462e-01 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.997462e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.997570e-01 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.997889e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.998223e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.998233e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.998541e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.998675e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.998755e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.998906e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999049e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999098e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999146e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999305e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999524e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999541e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999665e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999821e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999936e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999942e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999952e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999956e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.999965e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999973e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999984e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999985e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999989e-01 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.999993e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999994e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.999995e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999997e-01 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.999998e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999999e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999999e-01 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 9.999999e-01 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 1.000000e+00 | 0.000 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |